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The DNA Damage Response (DDR) is an evolutionarily conserved network of 
proteins that maintain genome stability in cells and serve as an anti-cancer barrier. The 
DDR is activated in early pre-neoplastic lesions and is often dysregulated or functionally 
deficient in late-stage neoplasia. The signaling and repair arms of the DDR pathways can 
serve as both cancer drivers and as important therapeutic targets. The following work is 
divided into two parts: (1) how altered double strand break repair pathways may serve as 
therapeutic targets for restoring sensitivity to DNA damaging agents in cancers and (2) 
the role of Mre11-Rad50-Nbs1 (MRN) complex, the first-responder to DNA double strand 
breaks, in pre-neoplastic lesions as a key cell-cycle regulator.  
TP53 deficiency has long been associated with poor patient outcomes and 
decreased response to DNA damaging agents, specifically radiotherapy. Chapter 2 of this 
dissertation identifies hyperactive end-joining pathways as a significant mediator of radio-
resistance. We show that p53-deficiency in an isogenic model system is sufficient to 
induce resistance to radiation. The resistance to therapy can be partially reversed with 
inhibition of DNA Protein Kinase (DNA-PK), a serine-threonine regulatory kinase involved 
in Non-Homologous End Joining. Further, we identify a potential resistance pathway that 
a subset of p53-deficient cells with inhibition of DNA-PK may employ to avoid cell-death. 
Finally, we suggest that dual-suppression of DNA-PK and Polymerase Theta may be a
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clinically relevant mechanism to restore treatment sensitivity in p53-deficient cancers.  
Our data show that repair of S phase DNA damage by hyperactive end-joining repair 
pathways mediates therapeutic resistance in p53-deficient cells.   
The MRN complex binds to DNA DSBs, activates master signaling kinases, and 
initiates end resection at the break to begin repair. Data in this dissertation demonstrate 
that the MRN complex regulates a p53-independent, G2/M checkpoint in response to 
burgeoning replication stress during oncogenesis. This checkpoint response regulates 
mitotic entry of under-replicated DNA, enabling cells with genome instability to exit the 
cell-cycle via permanent G2 arrest or by mitotic catastrophe. This checkpoint response 
provides insight into how the DDR restrains genome instability during oncogenesis.  
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CHAPTER 1 - INTRODUCTION 
1.1. Chromosomal Instability 
Cancer begins when a single cell acquires driver mutations to proliferate in an 
uncontrolled manner, eventually giving rise to tumors. In the process of expansion, there 
are two broad stages which are recognized as part of the genetic transformation. First,  
the initial mutational acquisition which allows for cancer development (i.e. the drivers of 
cancer) and second, an additional phase of diversification due to selection pressures 
during the evolutionary process1,2. Both processes give rise to inter- and intra-tumoral 
heterogeneity1,3. Tumor heterogeneity is a clinically relevant topic as it poses substantial 
challenges for therapeutic consideration and efficacy4,5. Chromosomal Instability (CIN) is 
a hallmark of cancer and considered to be a major instigator of tumor heterogeneity4,6. 
CIN is defined as ongoing genomic alterations that result in loss and/or gain of whole 
chromosomes, partial chromosomes, structural aberrations, and gross chromosomal 
rearrangements. These changes lead to somatic copy number alterations (SCNAs) which 
are prevalent across various types of cancers. Amongst the most common cancer types 
(lung, breast, and colorectal), up to 80% of these tumors are characterized by SCNAs 
and a lack of diploid karyotype7–9.  
The central questions addressed in this dissertation are how cells give rise to 
chromosomally unstable genomes that create complex genomic alterations and how 
these genomic insults are continuously tolerated in the duration of a cancer cell’s life. The
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 vast majority of cancer therapies rely on DNA damaging agents which cause cell death 
through the induction of cytotoxic double strand breaks (DSBs) in the genome10. Thus, 
the study of the origin, tolerance, and maintenance of genome instability will give us 
greater insight into novel therapeutic vulnerabilities of chromosomally unstable genomes 
to DNA damaging agents as well as resistance mechanisms utilized by cancer cells to 
avoid cell death.  
DNA damage is an umbrella-term that can describe a wide variety of genetic 
lesions that alter the chemical structure of DNA. Most DNA lesions alter one of the DNA 
strands and the other undamaged strand can serve as a template for repair to restore 
fidelity to the original DNA sequence. DNA DSBs are considered the most cytotoxic form 
of DNA damage because both strands of the double helix are cleaved and the DNA is 
fragmented10. The DSB lesion is highly mutagenic and can even serve as a nidus for 
chromosomal translocations. In mammalian cells, there are at least 10-50 DNA DSBs per 
day per cell that arise due to endogenous stressors11. It is imperative that the cell 
recognize and repair DNA DSBs quickly and efficiently by activating the DNA Damage 
Response (DDR). 
1.2. The Mammalian DNA Damage Response  
The DDR is an evolutionarily conserved pathway whose purpose is to maintain the 
genome and to protect it against both exogenous and endogenous forms of DNA 
damage12,13. DNA damage is considered to be exogenous when it is environmentally or 
extracellularly induced. Examples of exogenous DNA damaging agents include UV 
exposure, ionizing radiation, and clastogenic chemotherapies12. Endogenous DNA 
damage is more complex and often due to dysregulation of cellular processes13. 
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Currently, the most commonly recognized sources of endogenous DNA damage include 
reactive oxygen species, toxic metabolic accumulates, spontaneous deamination, errors 
in DNA replication or editing, inactivation of DDR pathway components, and oncogene 
activation14. In the context of cancer biology, the last two sources are considered key 
contributors to endogenous DNA damage.  
The DDR is composed of four categories of proteins: sensors, signal transducers, 
mediators and effectors12,15. Sensors bind to and recognize DSBs; the mammalian DSB 
sensor is composed of the Mre11-Rad50-Nbs1 trimer, known as the MRN complex16. 
Signal transducers are primarily master kinases that amplify the signal that a DSB has 
occurred and coordinate repair with cell-cycle control. Two important signal transducers 
in the eukaryotic DDR are the proteins Ataxia-Telangiectasia Mutated (ATM) and Ataxia-
Telangiectasia Related (ATR)17. While ATM is the primary master kinase for DSBs and 
ATR plays a similar role for single-stranded DNA (ssDNA) lesions, they have the ability 
to cross-talk and activate each other respectively17. Mediators are the DNA binding 
proteins that eventually mediate repair of the DSB. Examples of well-known mediators in 
cancer include the  Breast Cancer Gene 1 and 2  (BRCA1 and BRCA2). Finally, effectors 
are proteins involved in regulating the cell-cycle such that the cell has ample time to 
conduct repair prior to transitioning to the next phase of the cell-cycle. Therefore, effectors 
are often strong tumor-suppressors such as TP53, which enact DNA damage checkpoints 
or trigger apoptotic cascades if repair is unsuccessful18.  
There are three recognized DSB repair pathways: Non-Homologous End-Joining 
(NHEJ), Homologous Recombination (HR), and Theta-Mediated End Joining (TMEJ)19. 
NHEJ-based repair is the most rapid and dominant form of DSB repair in cells as it can 
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occur throughout the cell-cycle20. During NHEJ, as the name suggests, the broken 
fragments are directly ligated without utilizing a homologous template. The DSB is first 
recognized by two Ku proteins (Ku 70/80) which act as a platform for other NHEJ proteins 
to dock21. The next critical protein that is loaded is the DNA-dependent protein kinase 
(DNA-PK) whose catalytic subunit phosphorylates itself and other key proteins to trigger 
the NHEJ repair cascade21,22. Often, at the site of the DSB the DNA ends are fragmented 
in a manner that is incompatible with direct ligation and so, nucleases must first process 
the DSB to allow for the two ends to be joined. NHEJ is characterized by minimal removal 
of nucleotides to enable clean-up from either end of the break (5’ or 3’). The endonuclease 
Artemis performs resection after being recruited by DNA-PK. After resection, human DNA 
Pol X family polymerases (Pol  and Pol ) incorporate either dNTPs or even rNTPs 
(which are then removed by base excision repair) into the ends23,24. The unique feature 
of these polymerases is their ability to incorporate nucleotides in both a template-
dependent or independent manner. Thus, NHEJ is more error-prone than HR due to the 
incorporation of small INDELS (insertions/ deletions) at the site of the DSB lesion25. 
Finally, the last step is the NHEJ pathway is DNA ligation which is mediated by DNA 
ligase IV with XRCC4 activating the ligase complex26. Summarily, we can categorize the 
NHEJ pathway into sensors (Ku 70/80), transducers (DNA-PK), and mediators (Artemis, 
DNA X Family Polymerases, and Lig IV)20,22,23,26,27.  
In contrast to NHEJ, HR requires the presence of a sister template for 
recombination and is confined to phases of the cell-cycle where the chromosomes have 
been duplicated28. In addition to DSB repair, HR is also involved in rescue of replication 
fork collapse, and physiological processes such as telomere maintenance and 
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meiosis29,30. Accordingly, HR is both a mechanism for repair and a manner by which we 
enhance genetic diversity. Uninhibited HR can lead to accumulation of chromosomal 
rearrangements, toxic HR intermediates, and most importantly, a loss of heterozygosity30.  
HR begins with the MRN complex binding to DSBs as a dimer of trimers16. Mre11 
primarily exists bound to Rad50 in Mre112Rad502 complexes in vivo, and mutations in 
Mre11 are sufficient to de-stabilize the entire MRN complex and decrease levels of Rad50 
as well as Nbs131. These findings highlight that the complex is important for both function 
and protein stability. The globular domains of the Mre11 dimers are thought to enable 
“short-range” spatial organization of the broken DNA ends, and Rad50 dimers mediate 
“long-range tethering” via their zinc hooks31. Once MRN has bound to the DSB, it 
activates ATM master kinase and promotes autophosphorylation at S1981, which is key 
for retaining ATM at the DSB17. When ATM is activated, mediators and effectors are 
further recruited to the MRN complex. MRN is unusual in that it can participate in initial 
strand resection via its nuclease function32.  
Unlike NHEJ, HR is characterized by deep resection that leaves long ssDNA 
overhangs capable of strand invasion. Thus, processive resection enzymes such as 
hExo1 and DNA2 nucleases are required33,34. Following resection, the newly exposed 
ssDNA overhang is immediately protected by the binding of Replication Protein A 
(RPA)31. BRCA2 binds to the dsDNA-ssDNA junction and the formation of the BRCA1-
PALB2 (Partner and localizer of BRCA2)-BRCA2 complex is required for the recruitment 
of an essential HR protein: Rad51 Recombinase29,35. For HR to occur, the RPA must be 
displaced by the nucleation protein Rad51 in an ATP dependent manner36. Rad51 coated 
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filament must now find sequence complementarity through homology search and form a 
synaptic complex with the homologous genomic sequence.  
Homologous recombination is further complicated by the fact that there are two 
slightly different processes to synthesize and resolve the two different ends, which are 
known as the first-end and second-end synthesis steps34,37. Furthermore, because HR 
can result in crossover events where recombination occurs to induce genetic diversity, in 
the context of DNA DSB repair an altered version of HR is utilized, known as synthesis-
dependent strand annealing (SDSA), where crossover does not occur. SDSA is the 
preferred HR method in mitotic cells38. To simplify these key steps, it is hypothesized that 
Polymerase  is the primary polymerase involved in HR first-strand synthesis and other 
minor polymerases have been implicated for second-end synthesis respectively33. Once 
synthesis occurs, the HR complex is dissolved to complete repair. In summary, the key 
steps for HR are resection, strand invasion, homology search, strand pairing, and 
resolution.   
The final pathway, TMEJ has been an area of active investigation in recent years. 
The TMEJ pathway is not the first choice for DSB repair; however, in cases where either 
NHEJ or HR-based repair fails, it becomes essential39. Polymerase theta-mediated end 
joining is also important in disease states where the HR or NHEJ pathways are deficient 
or mis-regulated40. In particular, DNA Polymerase Theta (Pol ), the key polymerase-
helicase protein involved in TMEJ, is upregulated in many HR deficient cancers41. TMEJ 
is thought to be independent of classical-NHEJ and does not require Ku, DNA-PK, or 
other NHEJ factors to perform repair. However, TMEJ does require end resection which 
is thought to be initiated by HR initiating factors and this resection enables the search for 
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microhomologies flanking the break site. As a result, deficiency in proteins that prevent 
end resection (such as Ku or p53 Binding Protein – 53BP1) also leads to increased TMEJ 
usage39,41. The current accepted TMEJ repair pathway has the following five steps: 
resection, annealing of microhomology sites, flap removal, gap synthesis, and ligation. 
As previously mentioned, resection processes may be shared with HR, but excessive 
resection is not required to expose microhomologies. The flap removal is performed by 
ERCC1, and Pol  performs gap synthesis, with DNA Ligase III performing the final 
ligation step42. TMEJ is by nature an error-prone pathway as microhomology mediated 
repair often results in loss of the nucleotides in between the two sites of homology (i.e. 
due to flap removal).   
1.3. DDR AND THE CELL-CYCLE: THE DNA DAMAGE CHECKPOINTS  
The eukaryotic cell-cycle is characterized by four distinct phases: Gap phase 1 
(G1), Synthesis (S), Gap Phase 2 (G2), and Mitosis (M).  The sequential nature of the 
cell-cycle is coordinated by Cyclin Dependent Kinases (CDKs) and this elegant system is 
closely attuned to the DDR (Figure 1.2)18,43. The cell-cycle has several checkpoints that 
halt progress to ensure that DNA damage does not disrupt genomic integrity from one 
cellular generation to another44. DNA damage checkpoints can trigger cell-cycle arrests, 
providing time for DSB resolution. If repair is unsuccessful, downstream DDR effectors 
also have the capacity to trigger senescence or apoptosis. There are four main 
checkpoints: the G1-S transition checkpoint, intra-S checkpoint, G2 phase checkpoint, 
and Mitotic checkpoint (Figure 1.1)12,18,44.  
 The G1-S checkpoint is dependent on activation of the p53 tumor suppressor 
protein by ATM phosphorylation45. Activated p53 induces transcriptional upregulation of 
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CDKN1A, which results in production of p2146. Levels of p21 signaling determine the 
stringency of the G1/S checkpoint through inhibition of CDKs45,46. The second checkpoint 
in the sequence is the intra-S checkpoint. The most critical function of the intra-S 
checkpoint is to ensure replication fidelity47. ATR kinase is thought to be the more crucial 
mediator of the intra-S checkpoint as it can be activated by a wide variety of genotoxic 
insults unlike ATM, which is primarily activated by DSBs47,48. Activation of the intra-S 
checkpoint results in inhibition of further origin firing and allows time for replication forks 
that encounter DNA damage to undergo fork reversal or fork restart. However, several 
elegant studies show that the intra-S checkpoint does not behave similarly to the G1 or 
G2 checkpoints as the gap phase checkpoints often trigger an extended “arrest” of cell-
cycle49–51 Triggering the intra-S checkpoint is more often associated with a slowdown of 
S phase progression, prolonging the time spent in S phase49. In many cases, cells that 
complete S phase with substantial damage will then arrest or be halted by the G2 
checkpoint. The G2 checkpoint is termed the “threshold” checkpoint due to the 
observation that at a certain level of total DNA damage, this checkpoint is permanently 
activated, resulting in exit from cell-cycle49,52,53. The sensitivity of the G2 checkpoint is 
crucial as it is the final barrier before mitosis where entry of unrepaired DSBs can result 
in mitotic failure54,55. The final checkpoint is the mitotic checkpoint. The primary purpose 
of the mitotic checkpoint is to ensure proper attachment of spindle poles to chromosomes 









Figure 1.1 : DNA Damage Checkpoints. DNA damage is first detected by the MRN 
complex with downstream activation and cross-talk between ATM and ATR kinases58. 
These master kinases activate the checkpoint kinases, CHK2 and CHK1, which regulate 
p53 and Cdc25 respectively59. The CHK2-p53-p21 axis induces the G1/S DNA damage 
checkpoint59. ATR activation is critical for intra-S and G2/M checkpoints as it binds to RPA 
which coats single-stranded DNA at DNA damage sites in S phase replication forks58. 
CHK1 activity sequesters Cdc25C in the cytoplasm, causing G2 arrest. CHK1 activity also 
regulates Cyclin E through Cdc25A, which prolongs S phase via the intra-S checkpoint47. 
Finally, the spindle-assembly checkpoint serves as a major regulator for mitotic 
separation of chromosomes. Of note, these pathways have predominantly been 




While these four checkpoints have been broadly characterized, single-cell studies 
and analyses are revealing that activation of checkpoints can vary greatly within a 
population of cells treated with DNA damaging agents49,60–62. Insights from live-cell 
imaging have highlighted how cell-fate is dependent on the temporal kinetics of damage 
detection as well as repair71,80–82. Fluctuations in signaling and dysregulation of repair can 
greatly alter cell-fate outcomes in populations. Thus, critical portions of both chapter 2 
and 3 of this dissertation will utilize single-cell analyses to gain greater insight into the 
mechanisms of checkpoint activation and altered repair kinetics in states of DDR 
deficiency.   
1.4. The DNA Damage Response in Cancer 
Although the purpose of the DDR is to maintain the genome, components of these 
three pathways may  suppress or promote genome instability12. Alterations in DNA 
damage responses and repair can give rise to cancer. Many of the members of the DDR 
have been implicated in tumorigenesis63. The link between the DDR and cancer was first 
observed through the prevalence of cancers in human patients with genome instability 
syndromes64. Genome instability syndromes are characterized by a predisposition to 
early incidence of cancers, familial history of cancer, and recurrent incidence of multiple 
types of cancers64. These disorders are genetically characterized by germline loss of 
function mutations in key DDR proteins64,65 
Moreover, the oncogene-induced DNA damage response model in cancer 
proposes that the DDR is activated in early pre-neoplasia by the presence of oncogenic 
replication stress (Figure 1.2). Oncogene activation results in increased de-regulation of 
origin licensing, nucleotide synthesis, an imbalance in metabolic stress, and increased 
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replication fork collapse directly leading to the formation of DSBs. These DSBs activate 
the DDR via the MRN-ATM-p53 axis which in turn regulates anti-proliferative measures 
to inhibit tumor growth. However, continued activation of oncogenes and accumulating 
stress create selection pressures for DDR deficiency and dysregulation which then 
contribute to the development of neoplasia (Figure 1.2). Thus, the DDR is intrinsically 
linked to tumor development and progression.  
 
Figure 1.2 : Oncogene Induced DNA damage response (DDR) model. Mammary 
neoplasia is used as a model cancer to indicate how the DDR restrains early pre-
neoplastic lesions in response to oncogenic activation and accumulating DNA damage. 
DNA DSBs are sensed by the Mre11-Rad50-Nbs1 (MRN) complex which in turn activates 
master kinase Ataxia Telangiectasia Mutated (ATM) and downstream p53 signaling 
induces senescence or apoptosis.  In late-stage neoplasia, the DDR is often inactivated 
or dysregulated, giving rise to chromosomally unstable, clinically aggressive cancers. 
1.4.1. DDR Deficiency in Cancer 
DDR deficiency in cancer can be due to rare germline mutations or more often due 
to somatic mutations in DDR genes. Pan-cancer analyses of The Cancer Genome Atlas 
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datasets highlight that DDR gene alterations are highly common in cancer66. In fact, one-
third of all TCGA cancer types show somatic mutations in DDR genes in conjunction with 
high SCNAs and loss of heterozygosity66,67. Intriguingly, examining loss-of-function 
alterations within DDR pathways shows many co-occurring mutations in multiple 
pathways, highlighting the complexity of the DDR and its association with cancer68. 
Further, DDR alterations were also specifically correlated with higher mutational burden 
and diversity66–68.  
While these analyses speak to the DDR overall, alterations in the specific DSB 
repair pathways (HR, NHEJ, and TMEJ) are amongst the most common. In particular,  
HR pathway genes were altered in 40% of all cancers and in breast and ovarian 
carcinomas, HR alterations are ubiquitous69. Independent of HR alterations, in ovarian 
carcinoma, NHEJ defects were found in roughly 20 out of 47 patient primary cultures70. 
Moreover, mice with defects in Ligase IV, DNA-PKcs, Ku 80, or XRCC4 in a p53 deficient 
background all show accelerated tumor development70. Finally, TMEJ dysregulation in 
cancer has been the subject of several recent discoveries. Using microhomology based 
scar signatures to identify TMEJ repair sites, it was noted that up to 30% of TCGA cancers 
exhibit hyperactive Pol  repair41. These lines of evidence showcase the importance of 
DDR dysfunction in tumor origination and maintenance.   
1.4.2. Altered Responses for Therapeutic Sensitivity  
 Recent preclinical studies have provided evidence that DNA repair pathways 
should be viewed as a network71–74. When DNA repair pathways are dysregulated in 
cancer or if a patient is deficient for a key DNA repair protein, one or more pathways are 
simultaneously altered5,71. Studies have begun to explore the therapeutic potential of 
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exploiting DDR deficiencies. However, we limit ourselves if we only exploit synthetically 
lethal interactions between one or two target proteins within this vast network for 
therapeutic purposes. Synthetic lethality occurs when two or more combinations of gene 
expression deficiencies now result in cell-death whereas individual deficiencies are not 
sufficient for lethality75. For example, in HR deficient cells it is well known that inhibition 
of Poly-ADP-Ribose-Polymerase 1 (PARP) induces a synthetic lethality in the cells76. 
However, it is also known that in cells with HR deficiency, there is an increased 
dependence on NHEJ factors for resolution of endogenous DSBs77. This is further 
supported by the fact that dual knock-out of Atm and Prkdc (DNA-PKcs gene) results in 
embryonic lethality78. As a result, not only are HR deficient cells sensitive to inhibitors to 
PARP, they may also be sensitive to inhibitors of DNA-PKcs77,79. Moreover, they are likely 
to be highly sensitive to other inhibitors of NHEJ proteins and by extension; TMEJ80. 
Genetic evidence for this altered dependence is seen when we analyze “genomic 
scar patterns” of DDR defects. Signatures of Homologous Recombination Deficiency 
(HRD) may indicate upregulation of alternative end joining pathways that now contribute 
to DSB repair41,66,81. Analysis of Pol  dependent TMEJ repair patterns shows many 
similarities to signatures that have previously been labeled as HRD signatures41. 
Furthermore, continued discrepancies between HRD signatures and HR deficiency as 
assessed by HR functional assays suggest that HRD signatures are not predictive of 
repair capacity69,82–84. In the most recent study of the comprehensive repertoire of 
mutational signatures in human cancer, in conjunction with the Pan Cancer Analysis of 
Whole Genomes (PCAWG) cohort, it was noted that many of the existing signatures 
overlap significantly68. This study concluded that few DNA  repair “signatures” are unique 
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and many have strong associations with defective DNA-maintenance processes68. 
However, the biological processes by which these signatures arise are still unknown and 
remain to be categorized. 
Thus, these studies highlight how these pathway deficiencies may result in altered 
DDR responses. By viewing the DDR as a network of pathways that can alter functional 
capacity of any individual pathway to adapt to a deficiency, we can begin to identify 
personal therapeutic approaches for patients with known DDR defects.   
1.4.3. TP53 and the DNA Damage Response 
TP53 is the most commonly mutated gene in human cancers. As a result, TP53 
pathway deficiency is common in cancer and is associated with poor prognostic outcomes 
in many different cancer types85. The p53 protein is involved in numerous processes that 
respond to cellular stress86. As a tumor suppressor protein, p53 is also a downstream 
effector of the DDR, with involvement in DNA damage checkpoint functions and apoptotic 
activation61. In 80% of TP53 mutant cancers, both alleles are functionally impaired85. 
Despite substantial investigation into the physiological role of p53 and the long-standing 
observation that p53 deficiency leads to resistance to DNA damaging therapies, the DDR 
has not been systematically evaluated in a p53-deficient cell.  
There are several important knowledge gaps that exist regarding p53-deficiency 
and the DDR. First, TCGA mutational studies have drawn attention to cancer patient 
samples with dual loss of function mutations in ATM master kinase and TP5387,87–89. 
Classical epistasis models in genetics suggest that mutations in two proteins in the same 
pathway are epistatic to each other, i.e. one mutation masks the phenotype of the other. 
Since ATM and p53 are in the same DDR pathway, p53 mutation should mask the effect 
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of the ATM mutation. In this case, it would not be evolutionarily advantageous to further 
mutate ATM. However, the prevalence of patients with double mutations suggest that 
there are p53-independent functions of ATM that are critical for restraining cancer 
progression. Thus, one important knowledge gap in the field is to assess the p53-
independent functions of the DSB repair pathways. When the downstream effector is 
absent, what are the alternative mechanisms by which the MRN complex, ATM, and other 
components of the DSB repair pathway function to restrain tumorigenesis? Chapter 3 of 
this dissertation will investigate this specific question. 
Second, p53-deficiency has been linked to radio- and chemo-resistance since the 
1990’s90–93.  Yet the mechanisms of therapeutic resistance in p53-deficient cells and the 
possible involvement of DNA repair pathways remain to be characterized. Recent work 
in p53-signaling has demonstrated that epithelial cells with intact p53 have fluctuations in 
p53-signaling that dictate cell fate post DNA damage62. However, we have yet to fully 
uncover the modes by which cell fate decisions are made in cells lacking p53 altogether. 
As there are no personalized therapies for cancer patients with p53-deficiency, these 
studies aim to elucidate a clinically relevant mechanism that can be directly translated to 
meet this need.  
1.4.4. DDR and the Immune System  
The interplay between the immune system and the DDR is starting to become fully 
appreciated as studies reveal how the DDR activates components of the innate and 
adaptive immune responses during cancer progression and in response to cancer 
therapy. Tumor mutational burden is correlated to neoantigen load and activation of T cell 
responses against novel cancer antigens presented on cancer cells94,95. Defects in the 
 
 16 
DDR increase tumor mutational burden and give rise to frequent chromosomal 
translocations that can result in novel fusion onco-proteins, mutated self-proteins, or 
aberrant protein expression96. All of these may trigger adaptive T cell immune responses. 
Moreover, DDR dysfunction can lead to the presence of nucleic acids in the cytoplasm 
which trigger innate immune cells97,98. Nuclear compartmentalization of nucleic acids is 
critical for protecting self-DNA and for discriminating between self-DNA and infectious 
DNA viruses97. Pattern recognition receptors (PRRs) are viral detectors that detect 
nucleic acids99. Cytoplasmic and membrane bound PRRs can activate Type 1 Interferon 
responses, which are critical for antiviral defense and recruitment of phagocytic cells98. 
Thus, cytoplasmic DNA sensors exist to protect the cell from viral infection and due to 
their binding of double stranded DNA (dsDNA). They can also alert the immune system 
of cells whose nucleic acid material is present in the cytoplasm, because they are able to 
bind dsDNA98. During the cell-cycle, nuclear envelope collapse is the only time when 
nucleic acid material is not compartmentalized. Outside of this physiological scenario, 
there exists several pathological reasons for the presence of dsDNA in the cytoplasm. 
Cells with DDR dysregulation accumulate unrepaired DSBs leading to chromosomal mis-
segregation, which is known to increase dsDNA in the cytoplasm97. Intriguingly, dsDNA 
in the cytoplasm may be contained by a micronucleus (i.e. a portion of the nuclear 
membrane that now encloses the nucleic acid material)97. The DDR may also be involved 
in micronuclei formation100. However, micronuclei disintegration is common and often 
results in dsDNA entering the cytoplasm.  
Mitotic progression of DNA DSBs has been implicated as the major mechanism of 
the abscopal response101. The abscopal response is a radiotherapy term that describes 
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reduction of tumor size of tumors outside of the field of irradiation due to systemic 
effects102. Evidence now shows that the abscopal response is in part mediated by DSB 
presence in the cytoplasm and activation of cyclic GMP-Synthase (cGAS) and Stimulator 
of Interferon Genes (STING) which results in innate immune activation101. The benefits of 
this activation are a widespread effect on tumor reduction in tissues that were not part of 
the initial focal therapy. Thus, DDR defects in checkpoint responses may also contribute 
to mitotic DSBs resulting in increased genomic fragmentation during mitosis. Finally, there 
are well-documented patient cases of germline mutations in DDR proteins and 
cytoplasmic DDR sensors resulting in auto-immune disorders that trigger excessive 
inflammatory cascades in humans97,103. Thus, an understanding of how DDR proteins 
may contribute to mitotic DSB entry, micronuclei formation and immune activation is key 
to elucidating the in vivo implications of DDR dysregulation and tumor clearance. 
1.4.5. The Balance Between DDR and Genome Instability 
How can the DDR serve as an anti-tumor barrier (i.e. tumor suppressor) and also 
be utilized as a tolerance mechanism for tumor propagation and maintenance? This 
question has been of critical importance in the past decade as whole-genome and single-
cell sequencing have revealed the extent of the complexity found in a cancer cell’s 
genomic landscape67,104,105. Seminal experiments conducted in cancer tissues from the 
pre-neoplastic to neoplastic stages have shown how DDR mutations are progressively 
accumulated during cancer evolution106,107. In breast cancer, ductal carcinoma in situ 
(DCIS) enables us to study the pre-neoplastic mutations found in DDR proteins106. 
Commonly, pre-neoplastic cells retain p53 and rarely have DDR mutations. The initial 
lesions are often activating oncogenic mutations or amplifications in genes such as c-Myc 
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or epidermal growth factors108,109. Oncogenic activation, as discussed previously in Figure 
1.2, is an inducer of endogenous DNA damage which then activates the DDR. In early 
pre-neoplasia there are clear indicators of strong and sustained DDR activation. In late-
stage neoplasia, this activation is impaired or dysregulated due to the long-standing 
selection pressure to mutate DDR proteins13,63,106,107,110,111. As cancer evolves, the 
frequency of mutations in ATM and TP53 increases, suggesting that the transition from 
pre-neoplasia to neoplasia is restrained heavily by the presence of an active DDR.  
Simultaneously, as the DDR is inactivated, the cell experiences continuous 
endogenous DNA damage due to the persistence of oncogenic signaling. The cell is 
forced to repeatedly progress through the cell-cycle with endogenous DNA damage and 
in doing so, begins to depend on aspects of the DDR to avoid cell-death111–114. This 
results in unique DDR dependencies in late-stage neoplastic lesions as the DDR adapts 
to new cellular demands. These dependencies are evidenced by the existence 
chromosomally unstable cancers with highly variable sensitivity to DNA damaging 
agents115–118. Due to their ability to tolerate high levels of ongoing DNA damage, the 
addition of external clastogenic chemotherapies often may not induce cell-death. In these 
cells, we must elucidate the exact DDR pathways that become essential for cell survival 
to understand how these cells tolerate high levels of DNA damage.  
In summary, this dissertation will touch upon two key projects that address 
knowledge gaps in the field of the DDR in cancer. First, how does p53-deficiency 
contribute to therapeutic resistance and how are DNA repair mechanisms altered in p53-
deficient states? Second, what is the function of the MRN complex in a p53-deficient 
cancer, when the downstream effector of the cell-cycle checkpoint is no longer present? 
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How does MRN-activated DDR restrain tumor progression in early-stage neoplasia? 
Insights into these two topics will aid in our overall understanding of the complex role of 




CHAPTER 2 – DUAL INHIBITION OF DNA-PK AND DNA POLYMERASE THETA 
OVERCOMES RADIATION RESISTANCE INDUCED BY P53 DEFICIENCY 
 
2.1. Summary 
TP53 deficiency in cancer is associated with poor patient outcomes and resistance to 
DNA damaging therapies. However, the mechanisms underlying treatment resistance in 
p53-deficient cells remain poorly characterized. Here, we show that p53-deficient cells 
exhibit hyperactive repair of therapy-induced DNA double strand breaks (DSBs), which is 
mediated by DNA-dependent protein kinase (DNA-PK). Single-cell analyses of DSB 
repair kinetics and cell cycle state transitions reveal an essential role for DNA-PK in 
suppressing S phase DNA damage and mitotic catastrophe in p53-deficient cells. Yet, a 
subset of p53-deficient cells exhibit intrinsic resistance to therapeutic DSBs due to a 
repair pathway that is not sensitive to DNA-PK inhibition.  We show that p53 deficiency 
induces overexpression of DNA Polymerase Theta (Pol ), which mediates an alternative 
end-joining repair pathway that becomes hyperactivated by DNA-PK inhibition. Combined 
inhibition of DNA-PK and Pol  restores therapeutic DNA damage sensitivity in p53-
deficient cells. Thus, our study reveals DNA-PK and Pol  dependent end joining repair 
of S phase DSBs as critical determinants of response to DNA-damaging agents in p53-
deficient cells. Inhibition of these targetable DSB end joining pathways may improve the 




TP53 is the most commonly mutated tumor suppressor gene119. p53 mediates 
pleiotropic tumor suppressive effects through regulation of cell cycle arrest, apoptosis, 
and cellular metabolism in response to cellular stress86,120. Beyond its role as a tumor 
suppressor, p53 deficiency is associated with poor prognostic outcomes across many 
different cancer types85,121–123.  There is both clinical and preclinical evidence that p53-
deficient cancers exhibit resistance to a variety of DNA damaging therapies91–93,124–126.  
Despite accumulating evidence that p53 deficiency in cancer is associated with 
poor clinical outcomes, the mechanisms for therapeutic resistance in p53-deficient cells 
remain poorly characterized. Several factors play into the ambiguity surrounding the role 
of p53 and radio-resistance. First, early work suggested a role for loss of p53-mediated 
apoptosis in enabling increased survival post-radiation125,127.  However, in epithelial 
cancer cell models p53-induced cell cycle arrest, rather than apoptosis, has been 
associated with radiosensitization128. Yet, p53-mediated effects distinct from cell cycle 
arrest and apoptosis may also regulate radiosensitivity, as critical aspects of this 
relationship seem to be independent of p21 induction and the G1/S checkpoint129–131. 
Second, an important mechanism of cell death by DNA damaging therapy is mitotic 
catastrophe54,132,133. However, the determinants of therapy-induced mitotic catastrophe 
remain poorly understood. Third, further obscuring our limited understanding is a growing 
appreciation for the role of intratumoral heterogeneity as determinants of therapeutic 
response134.  Single-cell analyses are thus likely to reveal new insights into the 
underpinnings of treatment response in p53-deficient cells. Unfortunately, lack of 
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progress in understanding the mechanistic bases of therapeutic resistance in p53-
deficient cells has hampered efforts to better target p53-deficient cancers.    
The advent of time-lapse microscopy enables longitudinal assessment of 
biosensors at the single cell level, which has yielded novel insights into mechanisms of 
therapeutic response and p53-dependent cellular fate decisions61,135,136. Recent evidence 
highlights the importance of p53-signaling waves in regulation of cellular fate decisions of 
quiescence versus cell cycle re-entry after DNA damage 62,137,138. However, the 
mechanisms that determine such cell fate decisions upon DNA damage induction in p53-
deficient epithelial cells, which are prevalent in cancers, have not been established, and 
may lead to novel strategies to restore treatment sensitivity.  
In this study, we use time-lapse microscopy of cell cycle and DNA damage 
biosensors to investigate the relationship between therapeutic DNA damage and cell fate 
at the single-cell level. We find that p53-deficient cells exhibit hyperactive repair and 
accelerated resolution of DNA damage foci, particularly in S phase of the cell cycle. We 
show that the accelerated resolution of therapeutic DNA damage in p53-deficient cells is 
dependent on DNA-PK, a critical serine/threonine kinase in the non-homologous end 
joining (NHEJ) pathway139. Inhibition of DNA-PK using the small molecule inhibitor 
NU7441 partially restores sensitivity to DSB inducing agents in p53-deficient cells. We 
further demonstrate a role for Polymerase Theta (Pol ) mediated end joining (TMEJ), an 
alternative therapeutic resistance pathway in p53-deficient cells. Thus, our work provides 
critical insight into a clinically-relevant mechanism for why p53-deficient cells are resistant 
to DNA damaging therapies.  
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2.3. Results  
2.3.1. P53-Deficient Cells Exhibit Radioresistance and Accelerated Resolution of 
DNA DSBs 
 We first established an isogenic cell system to investigate determinants of 
treatment-induced cell fate in p53-deficient cells. In order to minimize potential 
contributions of accessory mutations on phenotypes observed in cancer cell line models, 
we used CRISPR/Cas9 to disrupt TP53 in the p53-proficient immortalized epithelial cell 
line model hTert-RPE1 (“RPE1”), which has also been a preferred model for investigating 
p53-dependent cell fate138,140,141. Two independent CRISPR/Cas9-targeted TP53-/- RPE1 
clones were selected for further study after confirming cells were deficient for p53 protein 
and lacked p53-dependent transcriptional induction of p21 in response to ionizing 
radiation (IR) (Figure 2.1A-C).  
 
 
Figure 2.1 : Isogenic model of TP53 Deficiency in RPE1 cells. A, Schematic of 
CRISPR target locus in human TP53 gene. Two sgRNAs were designed to target sites in 
the terminal region of exon 2 (which encodes the p53 transactivating domain) and a site 
in the downstream intron with a 36 nucleotide (nt) gap. sgRNAs were complexed with 
Cas9 in the RNP system and electroporated into RPE1 cells. B, Western Blot of 5 selected 
single-cell clones that were profiled for p53 protein. C, Functional assay evaluating p53-
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dependent CDKN1A  transcriptional responses to treatment of 5Gy IR. RNA from cells 
exposed to IR were harvested 6 hrs post treatment. 
 
To assess whether p53 deficiency confers a proliferative advantage when treated 
with ionizing radiation, we performed a mixed competition assay. We took mCherry 
labelled RPE1 and mixed them with equal numbers of unlabeled TP53-/- RPE1 or p53-
proficient RPE1 (control) (Figure 2.2A). We quantified the relative abundance of the 
unlabeled cells after to exposure to IR (0 – 6Gy), normalized to untreated samples at 
each timepoint. RPE1 labeled and unlabeled cells maintained stable representation 
across time and treatment conditions (Figure 2.2B).  Additionally, p53-deficient cells did 
not demonstrate a proliferation advantage in the absence of IR. However, treatment with 
IR at any dose level led to substantial positive selection for p53-deficient cells (Figure 
2.2C,D).   We also observed that p53 deficiency induced resistance to the radiomimetic 
clastogen Neocarzinostatin (NCS) by colony forming assay (Figure 2.2E-I). Thus, p53 




Figure 2.2 : TP53 Deficiency Confers Radioresistance. A, Live cell imaging procedure. 
Cells transfected with 10 nM si-control or si-TP53 for 48 h prior to imaging. 18 h into 
imaging, cells are treated with NCS (100 nM), DNA-PKi (.5 uM) or both and imaged for 
72 total hours.B, Relative abundance of unlabeled RPE1unlabelled over RPE1mCherry  
measured by Intellicyte high-throughput cytometry +/- SEM (n=6) is shown, normalized 
to the untreated (0Gy) cohort at each time point. C,D Relative abundance of unlabeled 
TP53 -/- Clone#1/ #2 measured by Intellicyte high-throughput cytometry  SEM (n=6) is 
shown, normalized to the untreated (0Gy) cohort at each time point. E, Clonogenic 
survival assays performed in RPE1 vs TP53-/- RPE1 cells exposed to NCS. F, 
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Clonogenic survival assays of RPE1 treated NCS +/- 0.5 uM DNA-PKi. Reported values 
are mean of n = 3 replicates, and survival fraction was calculated by first calculating 
plating efficiency and normalizing it to the untreated samples. G, TP53-/- RPE1 cells were 
treated with NCS +/- 0.5 uM DNA-PKi. H,I Representative colony forming plates for e and 
f at NCS doses of 0, 50 and 100 ng/ mL +/- 0.5 uM DNA-PKi.  Cell numbers for each 
conditions plated are the following: UT (500), NCS 50 ng/ ml (2000), NCS 100 ng/ ml 
(6000). 
 
Unrepaired DSBs can suppress proliferation through the engagement of DNA 
damage-induced cell cycle checkpoints.  We examined kinetics of DSB repair by 
performing immunofluorescence for 53BP1 and H2AX after treatment of p53 WT and 
TP53-/- cells with 5Gy IR (Figure 2.3). We observed a reduction in the number of 53BP1 
damage foci in TP53-/- cells as early as 30 minutes after treatment, that became even 
more pronounced by 4 hours post-treatment (Figure 2.3A,B).  Similar patterns of reduced 
foci formation were also apparent with H2AX staining at early timepoints (Figure 2.3C,D). 
Quantification of IR-induced DSBs by neutral COMET assay revealed an equivalent DSB 
burden induced immediately after 5Gy IR, irrespective of p53 status (Figure 2.4A,B).  
However, by 4 hours post-treatment, tail DNA percent was significantly reduced in the 
TP53-/-  cells while remaining elevated in p53-proficient RPE1 (Figure 2.4A,B). Thus, p53 
deficiency is sufficient to induce radioresistance and accelerated DSB repair in an 




Figure 2.3 : Accelerated Repair of DNA Damage Foci in TP53 Deficient Cells. A, 
Representative immunofluorescence images of 53BP1 foci in cells with indicated 
genotypes untreated (no IR) or treated with IR (5Gy) and collected at .5, 2, and 4 h after 
irradiation.  B, Quantification of 53BP1 foci. Data shown are mean (n=50 cells per 
treatment condition) SEM (n=3), and are consistent across two independent biological 
replicates. *p < 0.05; **p < 0.01; by two-tailed Student’s t-test. C, Representative 
immunofluorescence images of yH2AX foci in cells with indicated genotypes untreated 
(no IR) or treated with IR (5Gy) and collected at .5, 2, and 4 h after irradiation. D, 
Quantification of  yH2AX foci. Data shown are mean (n= 50 cells per treatment condition) 
+/- SEM (n=3), and are consistent across two independent biological replicates. *p < 0.05 






Figure 2.4 : Total DNA Damage Burden Assessment in TP53 Deficient cells. A, 
Representative Neutral COMET fluorescence staining for DNA tails in cells with indicated 
genotypes treated with or without 5Gy IR. For irradiated cells, 2 timepoints are shown: 
immediately after and 4 hours post IR. COMET tails and heads are denoted by 
OpenComet software analysis. B, Quantification of DNA DSBs via Neutral COMET assay 
reported as tail DNA percent at 0 and 4 hours post IR in RPE1 and two TP53-/- RPE1 cell 
lines. Data shown are mean (n= 50-150 cells per treatment condition) +/- SEM, and are 
consistent across three independent biological replicates. *p < 0.05; **p < 0.01; 
****p < 0.0001 by two-tailed Student’s t-test. 
2.3.2. Inhibition of DNA-PK Restores DNA Damage Foci Burden  
To directly assess the relationship between DSB repair kinetics, cell cycle status, 
and cell fate at the single cell level, we established a live cell imaging platform (Figure 
2.5A). RPE1 cells were dually labeled with PCNA-mCherry (to monitor cell cycle state 
transitions) and 53BP1-mVenus (to monitor DSB foci kinetics) (Figure 2.5B)49,60. To 
concurrently measure DSBs in real-time, 53BP1 is the preferred reporter for live-cell 
imaging. H2AX requires phosphorylation to become a marker for DNA DSBs and is 
therefore not compatible with live-cell reporter systems to assess DNA damage. These 
dual labeled cells were treated with scrambled siRNA  (si-Control) or siRNA targeting 
TP53 (si-TP53), the latter of which resulted in >90% knockdown of TP53 transcript and 
elimination of p53-dependent CDKN1A transcription in response to IR (Figure 2.5C). 48 
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hours after siRNA treatment, RPE1 cells were imaged for a total of 72 hours every 10 
minutes, and 18 hours into imaging, the DSB inducing agent was added (Figure 2.5A). 
To minimize time from radiation exposure to image capture and to induce equivalent 
DSBs in each population of cells, we utilized 100 ng/ml of Neocarzinostatin (NCS), a well-
known radio-mimetic. NCS has been previously utilized in studies evaluating DNA DSB 
repair in conjunction with live-cell imaging and has been shown to induce peak DSBs 
within 10 minutes of drug addition142,143. This experimental design allowed us to determine 
the cell cycle status of each cell within the asynchronous cell population at the time of 
NCS exposure. After NCS treatment, single-cell analyses for DSB repair foci kinetics and 
cell cycle outcomes were performed. As anticipated from the mixed-competition assays, 
analysis of global proliferation by live-cell imaging revealed significantly greater 

















Figure 2.5 : Overview of Live-Cell Imaging Platform A, Live cell imaging procedure. 
Cells transfected with 10 nM si-control or si-TP53 for 48 h prior to imaging. 18 h into 
imaging, cells are treated with NCS (100 nM), DNA-PKi (.5 uM) or both and imaged for 
72 total hours. B, RPE1 cell expressing the PCNA-mCherry and 53BP1-mVenus 
reporters. Cell cycle phases delineated by PCNA foci and DNA DSBs are marked by 
53BP1 foci. C, RT-qPCR for TP53 mRNA levels (left) and CDKN1A mRNA levels (right) 
in si-control treated vs. si-TP53  treated cells. To induce CDKN1A expression, cells 
irradiated at 5Gy and mRNA harvested 3 hrs post IR. D, Quantification of cell proliferation 
from live-cell imaging experiments for si-Control treated RPE1. Cell counts were 
normalized to cell numbers at start of imaging. Here we show one representative imaging 
beacon for each treatment condition (untreated, NCS 100 ng/ ml at 18 hours, and NCS 
100 ng/ml + 0.5 uM DNA-PKi at 18 hours). E, Cell proliferation counts for si-TP53 treated 




To analyze DSB repair kinetics in cells exposed to NCS, we tracked and quantified 
53BP1 foci in single cells and plotted heatmaps of damage foci burden over time from 
cell birth to mitosis (Figure 2.6A). Our results indicate that cells with functional p53 sustain 
high levels of damage foci in a prolonged manner after NCS exposure. In contrast, p53-
deficient cells on average developed a lower peak burden of 53BP1 foci after NCS 
treatment, with accelerated resolution of damage foci to baseline levels (Figure 2.6B). 
Moreover, p53-deficient cells also exhibited greater variance in 53BP1 foci burden and 
kinetics. Given the rapidity with which 53BP1 foci were being resolved, we hypothesized 
that hyperactive NHEJ may be contributing.  We thus performed the same experiment in 
the presence of an inhibitor of DNA-dependent Protein Kinase (DNA-PKi, NU7441 
0.5µM), which targets the central kinase in the NHEJ pathway144–146. Strikingly, DNA-PKi 
qualitatively abolished the difference in 53BP1 kinetics after NCS treatment between p53-
deficient and proficient cells (Figure 2.6B). To quantitatively assess the magnitude in 
damage burden, we calculated peak maximum 53BP1 foci values for each cell 
represented in the heatmap (Figure 2.6C). Consistent with the heatmap representation, 
the median peak foci count after NCS treatment was 40% lower in si-TP53 treated cells 
relative to controls (Figure 2.6C, p<0.0001).  Notably, DNA-PKi treatment resulted in a 
>2-fold increase in peak 53BP1 foci levels in the p53-deficient cells, whereas there was 
no comparable effect in control cells (Figure 2.6C). These results indicate that DNA-PK 






Figure 2.6 : Inhibition of DNA-PK Restores DNA Damage Foci Burden in TP53 
Deficient Cells A, Heatmap of 53BP1 foci tracings for single cells tracked from birth to 
mitosis or end of imaging. For si-control (n = 30 cells) and si-TP53 treated RPE1 (n = 60 
cells) treated with NCS 100 ng/ml. For visualization, cells are aligned to 10 frames prior 
to drug addition (black arrow). B, Heatmap of 53BP1 foci tracings for si-control ( n = 25 
cells) and si-TP53 treated RPE1 cells (n = 55 cells) treated with 100 ng/ml NCS + 0.5 uM 
DNA-PKi. C, Peak 53BP1 foci counts for cells treated with 100 ng/ml NCS or NCS+0.5 
uM DNA-PKi. Significance determined using two-tailed t-test. D, Area under the curve 
(AUC) analysis of 53BP1 burden showing integral DNA damage for cells treated with NCS 
vs. NCS and DNA-PKi. Cells are segregated into two groups: cells exposed to drug in G1 
vs. S phase ( n = 25-30 G1or S cells for si-TP53 cohort, n = 10-15 G1 or S cells for si-
control cohort). Significance determined by two-tailed t-test. ****p < 0.0001, ***p < 0.001, 
n.s. = non-significant. E, 53BP1 foci burden in G1 phase p53-deficient RPE1 upon 
exposure to NCS and DNA-PKi. Dashed line = S phase onset, blue line = mean 53BP1 
foci burden for all cells in G1 with NCS and DNA-PKi addition, orange line = mean foci 




Following this analysis, we studied the effects of DNA-PKi in different phases of 
the cell cycle during drug exposure. We used PCNA live-cell imaging to resolve cell cycle 
phase transitions in cells tracked for 53BP1 foci kinetics. We performed area under the 
curve (AUC) analyses in single cells to estimate total DNA damage burden during G1 and 
S phase after NCS exposure (Figure 2.6D). This analysis revealed that the diminished 
53BP1 foci burden observed in p53-deficient cells was most pronounced during S phase 
relative to control cells (Figure 2.6D). DNA-PKi treatment significantly increased S phase 
53BP1 burden in both si-Control and si-TP53 treated RPE1 cells (Figure 2.6D). While si-
TP53  treated cells in G1 were also affected to a lesser degree, we were curious to 
examine if the effect was in part due to loss of the p53-dependent G1/S checkpoint 
resulting in propagation of unrepaired DNA damage into S phase. Indeed, we found that 
DNA-PKi induced a drastic increase in 53BP1 foci as p53-deficient cells transitioned from 
G1 to S phase, which subsequently diminished over time (Figure 2.6E, p<0.00001 at t = 
start of S phase). Thus, DNA-PK is required for hyperactive resolution of clastogen-
induced DSB foci in p53-deficient cells, and most prominently during S phase. 
2.3.3. Checkpoint Responses Halt P53-Proficient Cells  
To investigate the association between DNA damage and activation of cell cycle 
checkpoints, we quantified cell cycle phase durations for all treatment conditions (Figure 
2.7A,B). Time-lapse microscopy of live cells expressing the PCNA biosensor enables us 
to deconvolute biological effects in different cell cycle stages without the use of any 
synchronization agents. Specifically, we separately evaluated the effect of NCS treatment 
on cells that were either in G1 or S phase at the time of drug addition. p53-proficient G1 
cells exposed to NCS induced a significant prolongation of G1, indicative of G1/S 
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checkpoint activation, with a substantial proportion of cells remaining arrested for the 
duration of imaging (Figure 2.7C).  Similarly, cells exposed to NCS in S phase exhibited 
a G2-M checkpoint (Figure 2.7D). p53-deficient cells exhibited no prolongation of G1 
duration after NCS, consistent with the notion that G1/S checkpoint activation is p53-
dependent (Figure 2.7E)53,147. DNA-PK inhibition did not alter G1 duration in either p53-
proficient or p53-deficient cells (Figure 2.7C,E). In contrast, DNA-PKi increased the 
duration of G2-M checkpoints irrespective of p53 status (Figure 2.7D,F).  These 
observations suggest that increased levels of S phase DNA damage induced by DNA-
PKi and NCS treatment (see Figure 2.6D,E) result in activation of a G2/M checkpoint that 
is, at least partially, p53-independent.  However, the duration of G2/M checkpoint 
activation differed by p53 status. While p53-proficient cells frequently remained arrested 
for the entire duration of imaging (open circles, Figure 2.7C,D), p53-deficient cells 
experienced a more transient prolongation of G2 duration followed by progression into 




Figure 2.7 : Cell Cycle Checkpoint Responses are Altered in TP53 Deficient Cells 
with DNA-PKi Treatment. A, Schematic depicting NCS treatment (50 ng/ml + 100 ng/ml  
for si-control and 100 ng/ml for si-TP53 RPE1) and/or NCS + 0.5 uM DNA-PKi treatment, 
and phase of the cell cycle cells are exposed to drug (G1). B, Schematic of drug treatment 
for S phase cells. C, Distribution of cell cycle phase lengths, each colored dot is an 
individual cell with untreated cells (no NCS) shown in black, NCS treated cells  shown in 
blue, and NCS+ 0.5uM DNA-PKi treated cells shown in red for si-control RPE1 in G1 
phase. n = 20 untreated and n = 30 treated cells (for each treatment cohort).  Statistical 
significance was determined by comparing untreated and treated groups at each phase.  
****p < 0.0001, n.s. = non-significant. Open circles indicate arrested cells that did not enter 
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the subsequent phase of cell cycle for remainder of imaging. D, Distribution of cell cycle 
phase lengths for si-control treated RPE1 in S phase, ***p < 0.001, ****p < 0.0001, n.s. = 
non-significant as evaluated by two-tailed t-test. E, Distribution of cell cycle phase lengths 
for si-TP53 treated RPE1 in G1 phase, ****p < 0.0001, n.s. = non-significant as evaluated 
by two-tailed t-test. F, Distribution of cell cycle phase lengths for si-TP53 treated RPE1 in 
S phase, ****p < 0.0001, n.s. = non-significant as evaluated by two-tailed t-test. 
 
2.3.4. Inhibition Of DNA-PK Induces Catastrophic Mitoses in P53-Deficient Cells  
We next used a heatmap representation to track the fate of individual cells from 
birth until mitosis (Figure 2.8).  Red bars indicate a mitotic catastrophe or apoptosis event 
(Figure 2.8A,B). The median cell cycle time for both untreated p53-proficient and p53-
deficient cells was approximately 22-24 hours. NCS treatment is indicated as a dashed 
line at the 18 hour timepoint. Individual cells are ordered according to cell cycle phase at 
the time of NCS treatment (G1 versus S) and eventual cell fate (viable, G1 arrest, G2 
arrest, or mitotic catastrophe/apoptosis). The majority (70%) of p53-proficient (si-Control) 
G1 cells exposed to NCS activated a G1 checkpoint that was maintained for the 
remainder of imaging (Figure 2.8A). 26% of these cells underwent G2 arrest or mitotic 
catastrophe, whereas only 3% retained their proliferative capacity (Figure 2.8A). Control 
cells exposed to NCS in S phase exhibited more diverse cell fates: 40% G2 arrest, 17% 
mitotic catastrophe, and 43% that retained proliferative capacity.  These observations, 
made using single-cell tracking of asynchronous cell populations, are consistent with 
observations of intrinsic radioresistance of S phase cells using cell synchronization 
methods90. In contrast, the majority of p53-deficient (i.e., si-TP53  treated) cells in G1 or 
S at the time of NCS treatment remained viable without perceptible engagement of any 
cell cycle checkpoints (Figure 2.8B, 80% and 87%, respectively). Consistent with prior 
53BP1 analyses, S phase cells are most sensitized to DNA-PKi as the addition of the 
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inhibitor increased G2 arrest frequency in control cells (40% to 91%), and increased 
mitotic catastrophe in p53-deficient cells (13% to 47%, Figure 2.8B, Figure 2.9). In total, 
the percentage of viable p53-deficient cells after NCS decreased from 87% to 47% when 
treated in S phase with DNA-PK inhibition (p<0.0001, Fisher’s exact test, Figure 2.8B).   
Despite the significant increase in mitotic catastrophe induced by combined 
treatment with DNA-PKi and NCS, 47% of p53-deficient cells exhibit intrinsic resistance 
to therapy with retained proliferative viability (Figure 2.8B). We hypothesized that levels 
of unrepaired DNA damage may be determinants of viable (i.e., resistant) versus non-
viable (i.e., sensitive) cell fates. To evaluate this hypothesis, we quantified integral DNA 
damage burden in p53-deficient RPE1 with viable versus non-viable mitotic outcomes 
(Figure 2.9C,D). The mean integral DNA damage burden was approximately 2-fold higher 
in non-viable cells, relative to cells that viably completed mitosis (Figure 2.9D, p<0.0001). 
Further analysis revealed that integral DNA damage burden in S phase was most highly 
associated with cell viability after drug treatment (Figures 2.9C).  In addition, we traced 
the average 53BP1 foci burden over time for these two cohorts (Figure 2.9E). Our results 
indicate that cells with non-viable mitotic outcomes have an increased peak value of DNA 
damage after treatment with DNA-PKi and NCS, which remains elevated over time  
(p<0.0001 at t=20 hrs, Figure 2.9E).  Conversely, these findings indicate that p53-
deficient cells that exhibit intrinsic therapeutic resistance may be utilizing compensatory 





Figure 2.8 : Inhibition of DNA-PK in TP53 Deficient Cells Induces Mitotic 
Catastrophe. , A, Cell cycle outcome analyses for si-control treated RPE1, dashed white 
line indicates drug addition, each row is an individual cell (n = 60 cells for NCS and n=60 
cells for NCS+DNA-PKi treatment). Colored bars indicate different phases of the cell 
cycle, legend shown with no treatment control for comparison. Cells with red bars at the 
end of mitosis indicate terminal cell cycle event (mitotic catastrophe or apoptosis). Event 




treated as separate cohorts. Fisher’s exact test was performed between -/+ DNA-PKi 
cohorts using 2 outcome groups (viable, vs. non-viable (arrested cells + terminal 
outcomes). ****p < 0.0001, n.s. =non-significant B, Cell cycle outcome analyses for si-
TP53 treated RPE1, dashed line indicates drug addition, each row is an individual cell (n 
= 60 cells for NCS and n=60 cells for NCS+DNA-PKi treatment). 
 
 
Figure 2.9 : Peak DNA Damage Burden Directly Correlates to Induction of Mitotic 
Catastrophe. A, Time stamped image sequence of apoptotic cell (PCNA channel shown). 
Cells that experienced nuclear degradation during cell cycle prior to mitosis were 
categorized as “apoptotic cells.” In this sequence a cell in G2 experiences cell death at 
27 hours post birth, with indication of mitotic attempt, with nuclear envelope collapse or 
presence of any daughter cells. B, Time stamped image sequence of cell that 
experienced mitotic catastrophe (PCNA channel shown). Cell undergoes nuclear 
envelope collapse (24:10), and attempts mitosis, in subsequent images fragmentation of 
nucleus is clearly visible with no viable daughter cells present. Cell non-viability during 
mitosis was defined as mitotic catastrophe. C, Integral DNA damage burden for p53-
deficient cells treated with NCS (100 ng/ml) and DNA-PKi (.5 uM) are calculated and 
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segregated by viable (black) vs. non-viable outcomes (red). Legend indicates which 
phase of cell cycle the cells are in during drug exposure, followed by the phase for which 
the burden is calculated. Ex: G1 cells G1 burden = cells in G1 during drug exposure and 
total damage burden in G1. Area under the curve (AUC) analysis was performed by 
plotting 53BP1 foci counts over time for each cell and integrating burden over time. 
Statistical significance was determined using two-tailed Student’s t-test. D, AUC analysis 
of 53BP1 damage burden in viable vs. non-viable p53-deficient cells that were treated 
with NCS and DNA-PKi. Statistical significance was calculated using a Mann-Whitney 
test comparing ranks. ****p < 0.0001 E, Dynamics of 53BP1 foci burden p53-deficient 
RPE1 segregated by mitotic viability. The red line corresponds to mean 53BP1 foci 
burden for all p53-deficient cells treated with NCS and DNA-PKi that undergo catastrophic 
mitoses, black line indicates mean foci value for p53-deficient cells with NCS and DNA-
PKi treatment that are viable post mitosis, ( n = 20 viable cells and n = 33 non-viable 
cells). 
2.3.5. P53-Deficient Cells Utilize Alternative End-Joining Pathways  
Prior studies have demonstrated that cells with NHEJ deficiency exhibit a 
compensatory increase in alternative end-joining repair mediated by DNA polymerase 
theta (Pol , gene POLQ)40,41,148.  Polymerase theta dependent end joining (TMEJ) of 
DNA DSBs is characterized by deletions and templated insertions that are flanked by 
short tracts of sequence identity, or microhomology (MH)148.  We found that POLQ 
expression was 10- to 20-fold higher in two independent TP53-/- RPE1 clones, relative to 
parental TP53 wild-type cells (Figure 2.10A).  POLQ is also overexpressed in TCGA 
breast, lung, bladder, colorectal, gastric, glioblastoma, pancreatic, prostate, melanoma, 
and uterine cancers with TP53 mutation, relative to their TP53 wild-type counterparts 





Figure 2.10 : POL Theta Expression is Upregulated in TP53 Deficient Cells and 
Cancers. A, RT-qPCR for POLQ mRNA levels in 2 TP53-/-RPE1 clones compared to WT 
RPE1. Significance was determined using two-tailed t-test. ****p < 0.0001, **p < 0.01. B, 
POLQ gene expression depicted as log2 values of TP53 wild-type vs. mutant cancers 
across a subset of TCGA tumor types. Tumor labels follow TCGA labeling format. BRCA: 
breast cancer, BLCA: B-cell lymphoma, UCEC: uterine cancer, PRAD: Prostate cancer, 
PAAD: pancreatic cancer, SKCM: melanoma, LUSC: lung squamous cell cancer, LUAD: 
lung adenocarcinoma, GBM: glioblastoma multiforme, STAD: stomach cancer, and 
COADREAD: colorectal cancer. ****p < 0.0001, ***p < 0.001, **p < 0.01, *p<0.05, as 
calculated by one-way ANOVA. C, Schematic of CRISPR target locus in human POLQ 
gene. Two sgRNAs were designed to target sites in the polymerase domain, with an 87 
nucleotide (nt) gap. sgRNAs were complexed with Cas9 in RNP system and 
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electroporated into RPE1 cells with a TP53-/- background to create double knockout cell 
line. D,E POLQ specific substrates were introduced into the TP53 -/- vs. POLQ-/-TP53-/- 
DKO cells to assess repair efficiency. Products were amplified and characterized by 
electrophoresis and end joining efficiency was normalized to RPE1 with POLQ 
expression. F, Sanger sequencing analysis of CRISPR edited locus in POLQ-/- TP53-/- 
RPE1 clones. The locus of interest was PCR-amplified and cloned into a TOPO vector 
for sequencing analyses. Each line of sequence shown was derived from a different 
TOPO clone and aligned to show differences. The POLQ-/-TP53-/- clone has 87bp 
deletion resulting in frameshift mutations. Red boxes indicated sgRNAs used for the 
CRIPSR. 
 
To assess whether hyperactive TMEJ contributes to therapeutic resistance of 
TP53-/- RPE1 cells to NCS and DNA-PKi, we sought to inhibit Pol . As pharmacological 
inhibitors of Pol  are not yet commercially available, we created a double knockout 
POLQ-/-TP53-/- RPE1 line (Figure 2.10C). Bi-allelic frameshift mutations in POLQ were 
confirmed by Sanger sequencing and functional deficiency was established using an 
extrachromosomal TMEJ repair assay (Figure 2.10D-F)148.  
To directly assess whether TMEJ repair is increased after DNA-PKi treatment, we 
analyzed chromosomal break repair patterns at a site-specific DSB in p53-deficient RPE1 
cells.  Cells were transfected with Cas9 ribonucleoprotein (RNP) complexes that target 
the LBR locus, with or without DNA-PKi149.  Genomic DNA was harvested 60 hours later 
and analyzed for break repair patterns using next generation sequencing (NGS) (Figure 
2.11A).  Target amplification and TIDE analyses confirmed high rates of target site 
cleavage in all samples transfected with a full complement of Cas9-RNP150. We applied 
a bioinformatic algorithm (ScarMapper, see methods) to characterize the spectrum of 
repair products with at least 0.1% prevalence, classified according to the size of left 
deletion (LD), right deletion (RD), insertion (Ins), and microhomology (MH) (ScarMapper 
Methods). Indels <5bp were categorized as NHEJ, with the predominant repair product 
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being a +A 1bp insertion149. TMEJ was defined as repair products whose frequency was 
diminished by at least 2-fold in POLQ-/- cells.  All other repair products were categorized 
as “Unclassified.”  DNA-PK inhibition in TP53-/- RPE1 cells results in a substantial 
reduction in NHEJ repair, with a compensatory increase in TMEJ to nearly 45% of all DSB 
repair (Figure 2.11B,C). In contrast, DNA-PK inhibition in POLQ-/-TP53-/- RPE1 cells did 
not result in a substantial increase TMEJ signature repair (Figure 2.11D,E).  However, a 
higher proportion of Unclassified repair products were detected (Figure 2.11D,E).  A 
limitation of NGS analysis of DSB break repair is that non-amplifiable target loci are not 
measured. Thus, we used digital PCR to quantify the LBR locus detection rate, relative 
to a control locus, upon inhibition of DNA-PK and/or Pol  (Figure 2.11F).  LBR locus 
detection rates were most reduced upon inhibition of DNA-PK and Pol , indicating an 
increase in unrepaired DSBs upon inhibition of both DSB repair pathways (Figure 2.11G). 
These observations confirm an essential role for TMEJ in compensatory repair of 





Figure 2.11 : TP53 Deficient Cells Utilize Alternative End Joining in the Absence of 
Active DNA-PK. A, Schematic depicting chromosomal break repair assay. TP53-/- , and 
POLQ-/-TP53-/- RPE1 are segregated into 2 cohorts (+/- 3 uM DNA-PKi). Cells are 
electroporated using Cas9-RNP-sgRNA-LBR and evaluated by next generation 
sequencing for break repair products at target locus. B, Horizontal bar chart 
representation of individual break repair products at LBR locus in TP53-/-  RPE1 by NGS. 
Position 0 denotes LBR locus cut site, with left and right positions denoting final INDEL 
size and orientation. Results are reported as average with SEM of n=3 independent 
biological replicates.  C, Histogram of overall frequency of repair of NHEJ, TMEJ, and 
Unclassified products in TP53-/-  RPE1 with or without DNA-PKi treatment. D, Horizontal 
bar chart representation of individual break repair products at LBR locus in POLQ-/-TP53-




denoting final INDEL size and orientation. Results are reported as average with SEM of 
n=3 independent biological replicates.  E, Histogram of overall frequency of repair of 
NHEJ, TMEJ, and Unclassified products in TP53-/-  RPE1 with or without DNA-PKi 
treatment. RPE1, TP53-/-, and POLQ-/-TP53-/- RPE1 cutting efficiency, all three cell lines 
have comparable levels of cutting efficiency with sgLBR. F, Schematic depicting digital 
PCR method for assessing LBR detection rate. G, Results of digital PCR assay on TP53 
-/- vs. POLQ-/-TP53-/- cells with -/+RNP and subsequently -/+ DNA-PKi (3uM). Average 
of 3 independent biological replicates are shown with SEM. Statistical significance was 
calculated using Multiple-t tests.  *p<0.05, **p<0.01. 
 
To determine the impact of POLQ inhibition on cellular viability, we performed 
clonogenic survival assays in the parental TP53-/- and POLQ-/-TP53-/- RPE1 lines treated 
with NCS with or without DNA-PKi.  Genetic deficiency in POLQ resulted in significantly 
reduced viability after NCS treatment, both without or with concomitant inhibition of DNA-
PK (Figure 2.12A). Thus, TMEJ represents an independent repair pathway that mediates 
resistance of p53-deficient cells to DSB-inducing therapy.  Notably, TP53-/- RPE1 cells 
with inhibition of both TMEJ and NHEJ repair pathways had comparable clonogenic 
survival to p53-proficient RPE1 cells. Collectively, these findings indicate that hyperactive 
end joining repair via NHEJ and TMEJ mediate resistance to DNA damaging therapy 
induced by p53 deficiency (Figure 2.12B). 
2.4. Discussion 
These results recognize enhanced DNA DSB end joining repair capacity as a novel 
component of therapeutic resistance induced by p53 deficiency, and that loss of functional 
p53 alone is sufficient to increase hyperactive repair. Concomitant analyses of DSB and 
cell cycle biosensors in live cells reveal mitotic catastrophe as the primary mode of 
therapy-induced cell death in p53-deficient cells, and DNA damage burden in the 
preceding S phase as a key determinant of this outcome. Our findings indicate that DSB 
end joining hyperactivity is critical for suppressing S phase DNA damage burden, and 
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thereby the likelihood of mitotic catastrophe (Figure 2.12B). These mechanisms are 
particularly relevant in p53-deficient cells, where the DNA damage-induced G1/S 
checkpoint is lost, and DSBs incurred in G1 phase are efficiently propagated into S phase 
(see Figures 2.6-8).  
 
Figure 2.12 : Graphical Summary. A, Colony forming efficiency assay evaluating TP53-
/- and POLQ-/-TP53-/- RPE1 after treatment with NCS (at 25 ng/ml, 50 ng/ml, and 100 
ng/ml) with or without .5 uM DNA-PKi, data shown are mean +/- SEM (n= 3). Statistical 
significance assessed with student’s two-tail test. ***p < 0.001, **p < 0.01, * p<0.05. in 
comparison to the survival curve of TP53 -/- + DNA-PKi. All individual data from each cell 
line are first normalized to no NCS and no DNA-PKi treatment (i.e. the plating efficiency). 
B, Graphical summary, hyperactive DNA-PK and Pol Theta enable accelerated repair of 
S phase DNA DSBs in p53-deficient cells (left panel), thereby preventing adverse DSBs 
from entering mitosis. This mechanism decreases the risk of terminal mitotic catastrophe 
which occurs when un-repaired DSBs enter mitosis (right panel). 
 
Although NHEJ Is conventionally considered to be most critical for repair in G1, we 
observed a relatively greater impact of DNA-PK inhibition on the fate of S phase cells 
after treatment with a radiomimetic. There are several potential explanations for this 
unanticipated observation. First, recent findings suggest that DNA-PK may be 
dispensable for synapsis formation during NHEJ151. Accordingly, repair of “simple” DSBs 
in G1 phase may have a reduced reliance on DNA-PK, whereas repair of more “complex” 
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DSBs in S phase may require DNA-PK, possibly in partnership with the nuclease 
Artemis152–154. Second, it is possible that DNA-PK inhibition may be more impactful in S 
phase due to trapping of Ku proteins at DSBs, which inhibits the activation of homologous 
recombination pathways155. Third, DNA-PK may be particularly important in early S 
phase, when sister chromatids are not broadly present.  Notably, we observed a 
prominent peak of unrepaired DSBs just as p53-deficient cells transitioned from G1 to S 
phase.  Our observation that DSB end joining hyperactivity in p53-deficient cells is highly 
sensitive to DNA-PK inhibition warrants further mechanistic investigation. Recently, 
CYREN (cell cycle regulator of NHEJ) has been proposed to be a cell-cycle phase specific 
inhibitor of the Ku70/80 heterodimer that is critical for restricting NHEJ  to G1156. It is 
therefore possible that p53-deficiency may transcriptionally reprogram cell cycle-
inhibitors of NHEJ to enable hyperactive repair, though that is beyond the scope of this 
study.   
Regulatory mechanisms that confer TMEJ hyperactivity in cancer are just 
beginning to be investigated, although transcriptional overexpression of POLQ has also 
been observed in breast and ovarian cancers with BRCA1/BRCA2 deficiency or 
mutations in other genes that confer Pol  synthetic lethality41,157. Recent work examining 
integrated pathway analysis of TP53 deficiency noted POLQ to be frequently 
overexpressed in TP53 pathway deficient cancers85. Our findings, in an isogenic p53-
deficient cell line model, indicate that this relationship may be causal. The mechanism for 
p53-dependent suppression of POLQ expression remains to be elucidated, and may 
entail the regulation of non-coding RNAs158. Pol   is an error-prone DNA repair 
polymerase and therefore it is also possible that wild-type p53 suppresses POLQ 
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expression as part of its role in maintaining genome stability. In particular, recent work 
has shown that depletion of p53 enhances hijacking of stalled S phase replication forks 
by Pol   and increases TMEJ activity at damage sites in p53-null cells compared to p53-
proficient cells159. The increased use of TMEJ can also be explained by the potential 
creation of more complex DSBs upon NHEJ suppression that serve as poor substrates 
for homologous recombination (HR). Indeed, the molecular mechanisms of NHEJ and 
TMEJ hyperactivity induced by p53 deficiency warrant further investigation.  
Clinically, a wide range of TP53 mutations in cancer are observed, some of which 
may potentially exert gain-of-function activity124,160. The current study demonstrates the 
effect of p53 deficiency on hyperactive DSB end joining repair and resistance to 
therapeutic DNA damage. However, whether these findings are also applicable to cells 
expressing TP53 missense mutations remains unclear. Evaluating the effects of different 
p53 mutations on DSB repair mechanisms and therapeutic responses remains an 
important topic for future investigation.  
Radiotherapy and other forms of DNA damaging therapy are employed in the vast 
majority of cancer patients161.  Resistance to DNA damaging therapy may thus explain 
the adverse clinical outcomes associated with TP53 mutations in many different cancer 
types85. Our study supports the investigation of DNA-PK inhibitors administered in 
combination with DNA damaging therapy (including radiotherapy) in patients with p53-
deficient cancers.  Additionally, as inhibitors of Pol  are currently in development162, our 
study suggests that combined inhibition of both DNA-PK and Pol  represents a promising 
strategy to reverse the therapeutic DNA damage resistance in p53-deficient cancers.  
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2.5. Materials and Methods 
2.5.1. Key Reagents 
All key reagents can additionally be found with catalog number and identifiers in 
Table 2.1. Table also includes detailed information on software used for analyses and 
algorithms available for image processing. 










633 (1:10,000 for IF)  





Antibody, Alexa Fluor 
488, (1:10,000 for IF)  





AC-15 (1:10,000 for 
WB)  
Sigma-Aldrich    Cat# A1978, RRID:AB_476692  
Rabbit Anti-53BP1 
Polyclonal Antibody 
(1:500 for IF)  
Bethyl  Cat# A300-272A, 
RRID:AB_185520  
Mouse Anti-p53 
(1C12) mAb Antibody (
1:1000 for WB)  





Antibody (1:500 for IF)  
Trevigen  Cat# 4418-APC-100  
Chemicals, Peptides, and Recombinant Proteins 






Trypsin EDTA  Gibco  25200-056  
Polyethylenimine, 
Linear (MW 25,000)  
Polysciences  23966  
Bovine Serum 
Albumin   
Fisher Scientific  BP9706-160  
Corning® Cell-Tak™ 
and Tissue Adhesive  
Corning  354240  
RNAiMax ThermoFisher 13778100 
Critical Commercial Assays 
PlasmoTest  Invitrogen  REP-PT1  
RNAeasy Plus Mini Kit  Qiagen  74136  
Comet Assay Kit  Trevigen   4250-050-K  
Q5® Hot Start High-
Fidelity 2X Master Mix  
NEB  M0494S  
NEBuilder® HiFi DNA 
Assembly Master Mix  
NEB  E2621L  
TOPO® TA Cloning® 
Kit for Sequencing  
Invitrogen  450030  
T4 DNA Ligase  NEB  M0202S  




Cas9 Protein and 
TracrRNA for Alt-R 
Electroporation  










Gift from Dr. Jeremy Purvis   (See Citations)  
hTERT-RPE1 ATCC  ATCC® CRL-4000™  
hTERT-RPE1-TP53-/- This paper 
hTERT-RPE1-TP53-/-
POLQ-/- 
This paper   
Oligonucleotides (sgRNAs and Primers) 
 sgLBR GCCGATGGTGAAGTGGTAA
G 
 Synthesized at: IDT 
 sgTP53_Exon2 TCGACGCTAGGATCTGACTG  IDT 
 sgTP53_Dwnstream_I
ntron 
GAAACTGTGAGTGGATCCAT  IDT 
 sgPOLQ_1 ACTACTCTCAGCTTGA  IDT 
 
 51 




LBR_Rev ACGCAGTGGCTAAATCATCC EtonBio 



















Human TP53 Si-RNA 
SMARTPOOL 






















ESR1 Genomic Locus 
Probe 
T+C+T +AT+G +A+CC TG 
(Locked nucleic acid probe with 
HEX) 
 
IDT (LNA : Locked Nucleic Acid 
Probe)  
LBR Locus Probe TGAGATTGAATGTAGCCTTT
CTGGCCCTAA (with FAM)  
 
LBR Nested Sequencing Primers 
Purple -> Binds genomic DNA 
Green -> Phasing portion of primer  
chr1:225423928-225424162 
Size:   235 base pairs 
Forward Primer:  114 base pairs left of cut 
Reverse Primer:  123 base pairs right of cut 






















































































Software and Algorithms 
Python ≥v3.5  G. van Rossum, Python 
tutorial, Technical Report CS-
R9526, Centrum voor Wiskund
e en Informatica (CWI), Amster
dam, May 1995  
https://www.python.org/  
Flow Jo   FlowJo™ Software (Mac) 
[proliferation assay analysis] 
Becton, Dickinson and 
Company; 2019.  
https://www.flowjo.com/  
Graphpad Prism v8  N.A.  https://www.graphpad.com/  
Fiji  Schindelin, J.; Arganda-
Carreras, I. & Frise, E. et al. 
(2012), “Fiji: an open-source 
platform for biological-image 





676-682, PMID 22743772, 
doi:10.1038/nmeth.2019 (on 
Google Scholar).  
CellProfiler  CellProfiler Program Citation:  
McQuin C, Goodman A, 
Chernyshev V, Kamentsky L, 
Cimini BA, Karhohs KW, Doan 
M, Ding L, Rafelski SM, 
Thirstrup D, Wiegraebe W, 
Singh S, Becker T, Caicedo JC, 
Carpenter AE (2018). 
CellProfiler 3.0: Next-
generation image processing 
for biology. PloS Biol. 
16(7):e2005970 / doi. PMID: 
29969450 (Research article) 
 
Analyst Software Citation:  
Jones TR, Kang IH, Wheeler 
DB, Lindquist RA, Papallo A, 
Sabatini DM, Golland P, 
Carpenter AE (2008) 
CellProfiler Analyst: data 
exploration and analysis 
software for complex image-
based screens. BMC 
Bioinformatics 9(1):482/doi: 
10.1186/1471-2105-9-482. 













GSL Biotech  https://www.snapgene.com  
Open Comet v1.3.1  BM Gyori, G Venkatachalam, 
PS Thiagarajan, D Hsu and MV 
Clement. “OpenComet: An 
automated tool for comet assay 
image analysis”,  










Supplementary and Code 




Genes  www.Ensembl.org  Ensembl v91  
 
 
2.5.2. Cell Culture  
TP53+/+, Fusion-Reporter (TP53+/+,PCNA-mCherry, 53BP1-mVenus),  TP53-/-, and 
TP53-/-POLQ-/- cells are hTERT immortalized RPE1. The fusion-reporter cell line was 
gifted by Dr. Jeremy Purvis and originally created utilizing lentiviral transduction of the 
dual reporters into RPE1 followed by single-clone selection for stably expressing cells.  
Cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM), with 10% Fetal 
Bovine Serum (Hyclone FBS) and 2mM L-glutamine (ThermoFisher). All cells were 
maintained at 37C in an atmosphere of 5% CO2. Cells were routinely tested for 
mycoplasma contamination using PlasmoTest (Invivogen).  
2.5.3. Establishment Of Stable Cell Lines  
To create the TP53 and POLQ deficient cell lines, we used the Alt-R-CRISPR-
Cas9 system (IDT). We performed Neon transfection (Invitrogen) and followed the 
manufacturer’s protocol with Alt-R HiFi Cas9 nuclease, crRNA and tracrRNA purchased 
from IDT. crRNA was designed using MIT CRISPR (http://crispr.mit.edu) to target Exon 2 
of the TP53 gene to create the TP53-/- cell line and the polymerase domain of the POLQ 
gene to create the TP53-/-POLQ-/-  cell line (Supplementary Figs 1,5). Forty-eight hours 
after transfection, cells were seeded for single clone selection. Restriction enzyme 
screening, western blots, PCR screening, and Sanger sequencing confirmed gene 
targeting, post which we performed functional tests.  
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2.5.4. Immunofluorescence  
Cells were fixed with 3% Paraformaldehyde for 15 min at room temperature, 
followed by permeabilization with 0.25% TritonX-100 in PBS. Cells were subsequently 
processed for immunostaining experiments using the antibodies listed below. Nuclei were 
visualized by staining with DAPI. The primary antibodies used were: γH2AX (1:500, 
Trevigen, 4418-APC-100), and 53BP1 (1:500 for immunofluorescence, Bethyl, #A300-
272A). The secondary antibodies were: FITC Goat Anti-Mouse IgG (H + L) (1:500, 
Jackson ImmunoResearch, 115-095-003) and FITC Goat Anti Rabbit IgG (H + L) (1:500, 
Jackson ImmunoResearch, 111-095-144). Images were acquired using the GE IN CELL 
2200 high through-put imaging system at 40x magnification. 
2.5.5. SI-RNA Treatment 
WT Fusion-Reporter RPE cells were passaged twice after -80 C thaw and plated 
on 12 well plates at a density of 100,000 cells/ well for siRNA treatment. Twenty-four 
hours post plating, cells were exposed to 10nM / well si-TP53 (SMART pool from 
Dharmacon), and si-Control (Non-targetting SMART pool from Dharmacon), in OPTIMEM 
with RNA-iMAX (ThermoFisher) as a transfection reagent. As a no-treatment control, cells 
were exposed to RNA-iMAX and OPTIMEM without siRNA. 48 hours post transfection, 
cells were transferred onto 12 well Cell-Tak coated glass plates (Cellvis),  at a 
concentration of 50,000 cells/well for imaging. Prior to imaging and at the end of imaging, 
samples were taken for RT-qPCR analysis of p53 mRNA to confirm si-RNA knockdown.  
2.5.6. Mixed Competition Assay - Flow Cytometry  
mCherry labelled and unlabeled hTERT-RPE1 cell lines were plated on 96 well 
plates at a 1:1 ratio (1500 cells each for a total of 3000 cells per well), and irradiated post 
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plating at 0, 2, 4, or 6 Gy, and left to grow. Irradiation was performed after cell plating to 
ensure time for cell adherence for both RPE1 and TP53 -/- RPE1. Cells were fully adherent 
at time of radiation (4h post-plating). At indicated timepoints cells were harvested by 
trypsinizing and quenching with PBS with 5% BSA. Cells were fixed with 2% PFA and 
subsequently transferred to V-bottom plates (ThermoFisher, #249570). Cells were 
quantified by flow cytometry using the Intellicyt iQue at a volume of 100 µL/ sample, 
collecting all events per well. For each condition, 6 biological replicates were collected.  
2.5.7. Time-Lapse Imaging Microscopy  
Cells stably expressing Proliferating Cell Nuclear Antigen (PCNA)-mCherry and 
Tumor Suppressor p53 Binding Protein 1 (53BP1) – mVenus  were treated with si-RNA 
for 48 hours prior to imaging. PCNA-mCherry and 53BP1-mVenus  fusion reporter is a 
gift from Dr. Jeremy Purvis and Hui Chao Xiao. Cells were plated on Cell-Tak (Corning) 
coated glass-bottom 12-well plates (Cellvis) with Phenol-free DMEM (Invitrogen) 
supplemented with 10% FBS, and L-glutamine. Twenty-four hours post plating, cells were 
image captured every 10 min for 72 h in the mCherry and mVenus fluorescence channels. 
18 hours into imaging, DNA-PK inhibitor (DNA-PKi, NU7441) was added at a 
concentration of 0.5 µM  / well, and/or Neocarzinostatin (NCS, Sigma-Aldrich) at a 
concentration of 100ng/ mL/ well. We commenced imaging every 10 minutes in both 
channels for another 48 hours. Fluorescence images were obtained using a Nikon Ti 
Eclipse inverted microscope with a 40x objective and Nikon Perfect Focus (PFS) system 
to maintain focus during acquisition period. Cells were maintained at constant 
temperature (37 °C) and atmosphere (5% CO2). Nikon, NIS Elements AR software was 
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utilized for image acquisition. Image analysis was performed on ImageJ – Fiji and Cell 
Profiler.  
2.5.8. Colony Forming Assays 
Cells lines used in the assay are indicated in the figures. Cells were treated with 
NCS and/ or DNA-PKi for twenty-four hours, after which we performed a media change. 
For all colony forming assays, cells were incubated for 10 days at 37 °C to allow colony 
formation. Colonies were stained by Coomassie blue and counted on day 10.  
2.5.9. Digital PCR 
Primers and 5’ hydrolysis probes were designed to specifically detect the copies 
of LBR locus. ESR1 locus was used as genomic control. Each reaction assay contained 
10 µLof 2x dPCR Supermix for Probes (No dUTP), 0.9 µmol/L of respective primers, 0.25 
µmol/L of respective probes, and 10 ng of DNA in a final volume of 20 µL. Droplets were 
generated using automated droplet generator (Bio-Rad catalog #186-4101) following 
manufacturer’s protocol. PCR parameters for LBR locus were 10 sec at 95 °C, then 40 
cycles of 94 °C for 30 sec, 60 °C for 30 sec, and 72°C for 2 min followed by 98°C for 10 
min with a ramping of 2 °C/sec at all steps. The PCR cycling parameters for ESR1 
genomic locus were 10 sec at 95 °C, then 40 cycles of 94 °C for 30 sec and 60 °C for 1 
min followed by 98°C for 10 min with a ramping of 2 °C/sec at all steps. After PCR 
amplification, droplet reader (Bio-Rad QX200™ Droplet Reader Catalog #1864003) was 
used to measure the end-point fluorescence signal in droplets as per the manufacturer’s 
protocol. The recorded data was subsequently analyzed with QuantaSoft software 




2.5.10. DNA Repair Assay  
Cell lines used in the assay are indicated in the figure.  5 × 105 cells were 
transfected with sgLBR2 and TracrRNA complexed Cas9 protein at final concentrations 
of sgRNA:tracrRNA duplex: 22 pmol and Cas9 : 18 pmol per reaction, with Neon 
transfection kit (Invitrogen) using 2 1350 V, 30 ms pulses in a 10 μL chamber. 60 hours 
post transfection, cells were harvested for genomic DNA extraction (Nucleospin). Part of 
the gDNA was utilized for Sanger Sequencing and TIDE analysis post amplification of the 
genomic LBR2 locus. For analysis of INDELs, 100 ng of gDNA was amplified using 
phased primers.  These libraries were indexed with the Illumina unique dual combinatorial 
indices.  Following pooling, 2 x 150 cycle sequencing was done on an Illumina iSeq™.  
INDELs were identified by comparing the target reference sequence to the resulting 





CHAPTER 3 – MRE11 MEDIATES A P53- INDEPENDENT G2/M CHECKPOINT 
RESPONSE TO ONCOGENIC ACTIVATION 
 
3.1. Summary 
The DNA Damage Response (DDR) is a critical anti-tumor barrier during 
tumorigenesis. Defects in the DDR give rise to clinically aggressive breast cancers with 
high levels of genome instability. In this study, we perform a CRISPR based in-vivo murine 
DDR screen that identifies Mre11 as the most crucial DDR gene that restrains tumor 
proliferation. Prior work on the Mre11 protein, an apical double-strand-break sensor in the 
DDR, has revealed that Mre11 deficiency gives rise to uncontrolled proliferation and 
genome instability in murine models of triple negative breast cancer. However, the 
mechanism by which Mre11 regulates these two processes remains unknown. We then 
utilize live-cell imaging in conjunction with an in-vitro primary murine mammary epithelial 
cell system to show that Mre11 mediates a potent p53-independent G2/M checkpoint 
response during oncogenic induction. The absence of Mre11 enables cells to increase 
entry into mitosis and remain viable post- mitosis with ongoing genome instability. We 
characterize a unique nuclear phenotype associated with Mre11 deficiency: aberrant 
micronuclei formation. Mre11 deficient mouse embryonic fibroblasts lack ability to form 
micronuclei in response to irradiation and are further characterized by a functional defect 
in interferon signaling in response to micronucleus formation. These results highlight the 
importance of Mre11 in early checkpoint responses in pre-neoplasia and indicate potential 
roles for Mre11 in innate immune signaling to clear senescent cells in-vivo. Clinically, 10%
 
 60 
 of triple negative breast cancers show Mre11 deficiency and increased sensitivity to 
chemotherapy. Recent work has also implicated ATR signaling kinase as a critical 
mediation of mitotic entry post-S phase; treatment with inhibitors to ATR have previously 
shown great potency in Mre11-deficient cancers. These results pave the way for potential 
utilization of ATR inhibitors in Mre11 deficient cancers with translational implications in 
human breast cancer.  
3.2. Introduction 
The DNA damage response (DDR) is activated in early pre-neoplasia and 
becomes dysregulated over tumorigenesis106,163–165. Several important discoveries 
highlight how the DNA damage response may be activated in early pre-neoplastic lesions; 
however, the DDR is composed of a vast network of proteins and the most critical genes 
essential for the anti-tumor functions and the exact mechanisms by which they operate 
to restrain tumor proliferation remain poorly characterized.  
To this end, we performed an in vivo murine DDR CRISPR screen to systematically 
evaluate which DDR genes are most critical for restraining tumor formation in a mouse-
model of c-Myc driven Triple Negative Breast Cancer (TNBC). Oncogene-induced DNA 
replication stress is the primary mechanism for DDR activation in the early stages of 
cancer and the c-Myc driven TNBC model has previously been utilized to study in-vitro 
effects of oncogenic induction on DNA damage and emerging chromosomal instability 
(CIN)166–170 Here, we report Mre11 as the top candidate from the in vivo screen with 12/40 
murine mammary tumors having significant enrichment for Mre11 small guide RNAs 
(sgMre11) compared to internal controls. 
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Mre11 is part of the trimeric Mre11-Rad50-Nbs1 (MRN) complex that primarily 
detects DNA double strand breaks (DSBs) in eukaryotic cells16. The MRN complex is 
often denoted as the “first responder” to DNA DSBs and its position in the apex of the 
DDR is well-warranted16,32. Genetically, Mre11 and Rad50 are evolutionarily conserved 
across all three domains of life, emphasizing their importance as the core catalytic 
components of the complex31. Germline mutations in the MRN complex give rise to a 
series of genetic syndromes collectively termed: Genome Instability Syndromes171. These 
syndromes predispose patients to having developmental abnormalities, cerebellar 
dysfunction, and a high incidence of cancers31,171. Furthermore, all members of the MRN 
complex are encoded by essential genes and knockdown of any of the three proteins 
results in embryonic lethality, highlighting the importance of MRN for eukaryotic viability 
and maintenance of genomic integrity31.  
Somatic point mutations in MRN complex proteins, particularly the scaffolding 
protein Mre11, are rare in cancer172–174. Additionally, gene alterations via deep-deletion, 
insertions or fusions, are also infrequent172–174. However, protein-based expression 
studies evaluating the presence of the complex have highlighted that MRN complex 
members are significantly depleted in up to 10% of Triple Negative Breast Cancers 
(TNBCs)170. Tissue microarrays evaluating MRN expression in epithelial ovarian cancer 
(EOC) have shown that MRN complex is undetectable in 41% of low-grade and 19% of 
high-grade EOC’s175. In contrast to patterns of MRN deficiency in ovarian and breast 
carcinomas, over-expression of MRN has been detected in clinically aggressive colorectal 
cancers176,177. While it is unclear how MRN deficiency is induced, it may be that post-
transcriptional regulatory mechanisms may contribute to the patterns of MRN deficiency 
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seen, these recurrent observations of MRN deficiency in cancer along with the results of 
the in-vivo screen highlight the importance of this complex in restraining tumorigenesis.  
To understand the role of the double strand break sensors in cancer, it is critical to 
review the role that the MRN complex may serve as an anti-tumor barrier. During 
oncogenic activation in early pre-neoplastic lesions, cells experience tremendous 
replication stress. Endogenous replication stress is defined as the deregulation of DNA 
replication resulting in increased replication fork collapse and subsequent DNA damage. 
Replication fork collapse can lead to DSBs and/ or long stretches of single-stranded DNA 
(ssDNA). Recent work from our lab has shown the Mre11 is critical for prevention of 
replication fork collapse when oncogene-induced misfiring of origins increase replication-
transcription collisions170. Moreover, prior work has also shown that Mre11 deficiency 
increases tumor hyper-proliferation and genome instability170.  These previously reported 
phenotypes of Mre11 are both p53 and ATM-independent170. ATM is a member of the 
Phosphatidylinositol-3-kinase-like Kinase family (PIKK) and is a serine master kinase with 
numerous target proteins including ATR and p53144.  ATR is a sister kinase of ATM and 
binds to ssDNA that has been coated with RPA; and it is well-known that ATM and ATR 
have the ability to  cross-talk17.  ATM directly phosphorylates p53 and canonical 
depictions of the DDR pathway often portray p53 as a downstream effector with respect 
to regulation of the G1/S checkpoint and apoptotic responses to DNA damage46. 
However, in many cancers p53 is mutated, absent, or suppressed by over-expression of 
MDM266. In these situations, the role of the MRN complex becomes unclear because the 
downstream effector is functionally absent. 
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The goal of this study was to investigate the role of DDR proteins in serving as an 
anti-tumor barrier in pre-neoplastic lesions and to define the mechanisms by which the 
top candidate in our screen, Mre11, regulates tumor proliferation and genome instability. 
We use an in vivo DDR CRISPR screen and derive 40 mammary tumors to evaluate loss 
of which DDR proteins is most conducive to mammary tumor formation. We use live-cell 
imaging to first characterize the effect of Mre11 dysfunction in tumor proliferation. We 
characterize a p53-independent G2-M checkpoint function that is mediated by Mre11 to 
prevent mitotic entry of DNA damage and to subsequently eliminate cells with CIN. MRN 
deficiency also promotes ongoing genome instability in early G1 of daughter cells, 
highlighting transmission of under-replicated DNA through mitosis. Finally, we showcase 
an exciting role for Mre11 in mediating innate immune signaling via micronucleus 
formation. These results provide a mechanistic understanding for Mre11 and how it 
functions as a critical anti-tumor barrier.  
3.3. Results and Discussion 
To investigate the principal DDR genes involved in restraining tumorigenesis, we 
performed the in-vivo CRISPR DDR library screen utilizing a Cre-inducible mouse model 
of Triple Negative Breast Cancer (TNBC) (Figure 3.1A). TNBC is characterized by near 
universal p53 loss and a high incidence of co-occurring c-Myc overexpression (OE). Thus, 
p53 deletion and c-MycOE are 2 major drivers of TNBC, a cancer sub-type known for its 
complex genomic instability and oncogenic replication stress. Moreover, DDR 
dysregulation and mutations in core DDR genes have previously been reported in human 
TNBCs. To generate this model, we first crossed Rosa26Cas9/Cas9 to Rosa26MycOE-CD2/ 
MycOE-CD2 (OE = overexpression) to make Rosa26Cas9/MycOE-CD2 mice capable of over-
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expressing a c-Myc cassette under a Cre-dependent locus. We then bred the 
Rosa26Cas9/MycOE-CD2 to Trp53fl/fl mice (a gift from Dr.Perou) to generate the target mouse 
line with both inducible p53 deficiency and c-Myc overexpression: Rosa26Cas9/MycOE-
CD2Trp53fl/fl (Figure 3.1B). In addition, expression of CRISPR Cas9 endonuclease enables 
editing of multiple mouse genes upon exposure to short-guide RNAs for in vivo or in vitro 
experiments.  
The DDR CRISPR library is a custom, previously published pooled resource of 
sgRNAs that target 309 murine DDR genes (10 guides per gene) and also contains 834 
non-targeting sgRNA controls41. The DDR library was cloned into a Lenti-CRISPR-Cre-
V2-Lumifluor plasmid (see methods) and introduced to murine mammary glands via 
lentiviral intraductal injections (Figure 3.1A). The benefits of this model include 
spontaneous tumor generation post Cas9 mutation of targeted DDR genes and the 
presence of an immunocompetent landscape that more closely aligns to the human 
mammary tissue. The lentivirus with Cre-recombinase activates Cas9-GFP expression, 
removes a stop codon in front of a c-Myc cassette, and introduces deletion of Trp53 exon 





Figure 3.1 In-Vivo DDR Library Screen. A, Schematic depicting the in-vivo DDR 
CRISPR library screen. Female mice aged 6-10 weeks were bilaterally injected with 
lentivirus containing 3090 targetting sgRNAs, 834 non-targetting controls and Cre-
recombinase. 2 mice were sacrificed each at weeks 1,3,6,9 and 12 for hyperplastic gland 
sampling. B, Depiction of the Cre-recombinase activated genotypic changes in mouse 
model of TNBC. Myc-Overexpression (OE), Cas9-GFP expression, and Trp53 deletion 
were Cre-recombinase dependent.  C, Survival curve indicating the tumor free survival 
per mouse. Tumor free survival was calculated by bi-lateral palpation of mice weekly. 
Data represents the first day palpable tumor was recorded. All mice in the study barring 
the 10 sacrificed for hyperplastic sampling at early time-points, developed tumors. 
 
3.3.1. IN-VIVO DDR Library Screen Reveals Key Genetic Targets In Mammary 
Tumor Formation 
At the start of the study, 40 female mice from 6-10 weeks of age were bilaterally 
injected with the DDR-CRISPR lentiviral library at a multiplicity of infection of 1 to ensure 
that each mammary epithelial cell would only receive 1 sgRNA and then compete during 
tumorigenesis (Figure 3.1A,C). The tumor free survival curve is shown per mouse in 
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Figure 3.1C. These mice were followed post-injection until tumor growth equaled 15 mm 
in either of the right or left mammary glands, at which point tumors were harvested and 
stable cell lines generated. At the end of the study, which spanned 200 days, 43 total 
tumors were harvested from the cohort. 40 of these tumors met the tissue size 
requirement for sequencing analysis (Figure 3.1C and see methods). Several mice had 
multiple discrete tumors per gland resulting in the final number of tumors exceeding the 
total mice in the study. Post tumor-DNA extraction, we sequenced each sample to 
determine abundance of DDR sgRNAs in each tumor (gland z-Score) compared to the 
original DDR library plasmid (Plasmid z-Score) that was sequenced to calculate fold 
enrichment (Figure 3.2A-C). sgRNA enrichment in each tumor cohort was used to 
determine which DDR genes were most essential for mammary tumor formation starting 
from the hyperplastic lesions (shown as Days 7 and 21 in Figure 3.2A,B) to neoplastic 
lesions (mammary tumors, Figure 3.2C). Our results show the sgRNA with highest 
abundance across the most tumors (12/40) is sgMre11a which targets the Mre11 gene 
(Figure 3.2D).   
sgMre11a was detected as the singular sgRNA in 2/12 tumors and in 10/12 was 
found with other sgRNAs targeting the following DDR genes: Trp53bp1 and  Lmo4. These 
genes encode the p53-Binding Protein 1 (53BP1) and the Lim domain transcription factor 
4 (Lmo4) respectively. Of these, 53BP1 binding protein is a well-known DSB binding 
protein and marker of DNA damage. Intriguingly, other MRN complex members (Rad50 
and Nbs1) were not major hits in the screen, suggesting that Mre11 is the most critical 
member of the trimeric complex. These results also highlight potential synergistic 
pathways that may act to inhibit proliferation together. The results of the screen also 
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highlight Mre11a deficiency as a critical mediator of tumorigenesis compared to other 
DDR genes. Moreover, evolving work in the field of Mre11 has recently highlighted the 
critical roles of Mre11 in replication fork protection, fork rescue, genome maintenance, 
and proliferation in response to replicative stress. Thus, we decided to further evaluate 
the mechanistic role of Mre11 with respect to proliferation and genome stability.  
 
Figure 3.2 : DDR Screen Results. A, Shows DNA sequencing results from a hyperplastic 
mammary glands (n=4) harvested day 7 post-intraducal injection. The Plasmid Z score is 
determined by sequencing the individual sgRNA frequencies found by sequencing the 
pooled DDR library plasmid utilized for lentiviral generation. The sgRNA Z score was 
calculated by determing the frequency of sgRNA reads specific for each DDR gene 
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sequenced from the hyperplastic sample. Upward deviation from the mid-line indicates 
increased abundance in tumor (as shown by red circles), whereas negative deviation 
indicates depletion in the tumor (gray circles not essential for tumor formation). B, sgRNA 
abundance in day 21 hyperplastic glands (n=4) where the top sgRNA was Protein 
Arginine Methyltransferase (Prmt2). Mre11a is also indicated in this graph. C, Sequencing 
results indicate sgRNA abundance across all mammary tumors (n=40). sgMre11a was 
found in abundance in 12 total tumors, making it the most frequent sgRNA that was 
present across all mammary tumors in the study. In 2/12 tumors sgMre11a was the single 
most abundant sgRNA detected. 
 
3.3.2. Cell Cycle Profiles Of MRE11 Deficient Cells 
In order to clarify the role of MRN complex in restraining proliferation during cancer 
progression, we utilized the same mouse model in a series of in-vitro studies evaluating 
Mre11 in the context of cell-cycle regulation. Previously, MRN complex has been studied 
utilizing exogenous DNA damage; specifically, damage induced by ionizing radiation (IR). 
Using IR, others have shown that MRN complex is important for G2 checkpoint responses 
that are ATM dependent. However, as most of these experiments were performed in the 
presence of high levels of genotoxic DSBs; it is unclear how Mre11 responds to 
endogenous replicative stress. Prior results from our lab have also shown that the 
proliferative advantage conferred by Mre11 deficiency is not recapitulated by treatment 
with inhibitors against ATM or by deleting p53. This raises the exciting possibility that the 
proliferation advantage we are observing is both an ATM and p53-independent function 
of Mre11. Given the previous findings regarding Mre11 complex and its role in activating 
DNA damage checkpoints, we then proceeded to assess presence or absence of 
checkpoint responses in a primary murine mammary epithelial cell system (pMMECs, 
Figure 3.3A).  
The pMMEC in-vitro model system enables extraction of primary murine mammary 
epithelial cells, viral transduction to induce the same genotypic drivers utilized in the 
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screen, and downstream analysis of the initial cell-cycles post-oncogenic induction. To 
induce Mre11 deficiency in the pMMEC system, we utilized the same sgMre11 used in 
the CRISPR screen, a previously published sequence170,178. sgMre11 recapitulates a 
patient-derived Ataxia-Telangiectasia Like Disease (ATLD1) mutation in the C terminus 
of Mre11 to destabilize the transcript, and thereby the entire protein complex resulting in 
functional deficiency of the MRN complex in cells of interest (Figure 3.3B). Taking 
advantage of the large protein domain similarities between murine and human Mre11, 
sgMre11 targets the scaffolding region of Mre11 that docks to Rad50 to create the 
complex. To introduce the ATLD1 mutation, we created a short-guide (sg) RNA against 
amino acid R611, to induce a small deletion using CRISPR-Cas9 resulting in a premature 
stop codon and truncated protein product in murine cells (Figure 3.3B). This particular 
Mre11 mutant retains the endonuclease domain that is essential for cellular viability but 
lacks the scaffolding domain that is critical for MRN complex formation. The Mre11-ATLD 
mutant does not have the ability to localize to DNA DSBs and does not form a complex 
with Rad50 and Nbs1, thereby making it functionally DDR deficient.  
To evaluate cell-cycle profiles we combined the pMMEC system with live-cell imaging 
(Figure 3.3A). We co-infected pMMECs of interest with a lentivirus for Proliferating-Cell 
Nuclear Antigen (PCNA) fused to the mCherry reporter. PCNA is part of the replication 
ring clamp that slides along with the mobile replication fork during S phase, resulting in 
discrete formation of PCNA foci in S phase of the cell cycle. When combined with live-
cell imaging, this reporter can be utilized to reliably evaluate various phases of the cell 




Figure 3.3 : Live-Cell Imaging of pMMECs. A, Schematic of the in-vitro pMMEC system 
utilized in conjuction with live-cell imaging. The two mouse genotypes from which 
pMMECs were harvested are listed along with the timeline leading up to imaging. Cells 
were transduced once daily for two days with Lentivirus (LV)-sgRNA+Cre and LV-PCNA-
mCherry. Imaging was performed for 72 hours with image acquisition in the GFP (Cas9 
activation) and mCherry channels every 20 min. B, Representation of the ATLD mutation 
induced by sgMre11. The scaffolding region int he C-terminus of Mre11 for the Mre11-
Rad50-Nbs1 (MRN) complex is lost in the ATLD1 mutant, which is a truncated protein of 
610 amino acids (aa). C, Prolfierating cell fraction as quantified by a cell experiencing 
either S phase or mitosis in the 72 hour imaging period, OE = over-expression. n=185, 
235, 128, and 102 cells total per condition (left to right) respectively. D, Quantification of 
frequency of G2/M arrest in cells that completed S phase in sgControl vs. sgMre11 treated 
cohort (n=45 sgControl and n=62 sgMre11 cells). p<0.01 = ** as evaluated by Fisher’s 
exact test. E, Individual length of different cell-cycle phases for sgControl vs. sgMre11 




3.3.3. Proliferation Phenotypes In Mammary Epithelial Cells 
Due to the genetic complexity of late-stage neoplastic lesions, we decided to 
sequentially mutate mammary epithelial cells (MECs) that were harvested from mice to 
study Mre11 through tumor progression. The genetic manipulations in these pMMECs 
were performed utilizing lentiviral co-infection with lentiviral-sgMre11-Cre or lentiviral-
sgControl-Cre to induce c-Myc-activation and/or p53 deficiency in cells from 2 different 
mouse genotypes (Figure 3.3A). To evaluate pMMECs via live-cell imaging required the 
pMMECs to be propagated on glass with Cell-Tak (see methods). We established a 
protocol where pMMECs can be co-cultured on a selective feeder layer of rat-derived LA7 
fibroblast cells that mimic the stromal environment of breast tissue. These LA7 feeder 
cells can further be irradiated at 70Gy to prevent proliferation. To differentiate between 
feeder cells and pMMECs on imaging we utilized double positive (eGFP+, mCherry+) 
cells for our analysis. This ensured selective analysis of cells with Cre-inducible Cas9 
expression that had been infected by our lentiviral Cre along with the PCNA reporter 
(Figure 3.3A). Thus, our studies first established the feasibility of performing live-cell 
imaging in primary MMECs that had not been immortalized.  
Cells were imaged every 20 minutes for a total duration of 72 hours (Figure 3.3A). 
We first imaged unperturbed pMMECs derived from Rosa26Cas9/Cas9 mice that received 
Cre with no sgRNA to assess cell cycle lengths and general attributes of these pMMECs. 
We assessed infection efficacy and found at minimum 67-70% of the pMMECs were 
double-positive for eGFP and mCherry. In many of our studies, the transduction efficacy 
was high enough to enable analysis of >90% of all cells within the field of view. Our initial 
analysis of these Cas9 expressing pMMECs resulted in the observation that the majority 
of the cells harvested are quiescent, undergoing no cell cycle activity for the duration of 
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imaging (Figure 3.3C). We also clarified that co-transduction with the PCNA-mCherry 
promoter alone did not confer any discernible increases in proliferation capacity. To 
perform this analysis, we analyzed cells that remained within the field of view for the entire 
duration of imaging and recorded all observable cell cycle events. Cells that did not have 
any replication, birth, or mitotic events for the entirety of imaging were labelled as 
quiescent. In this manner we were able to evaluate the proliferation index of each imaging 
cohort.  
Next, we assessed the proliferation index of pMMECs with MycOE, 
MycOEMre11ATLD/ATLD, MycOETrp53-/-, and MycOETrp53-/-Mre11ATLD/ATLD pMMECs (Figure 
3.3C). With each manipulation we noticed a substantial increase in the proliferation index. 
Intriguingly, while the other alterations increased the proliferation index nominally, loss of 
Mre11 induced the most significant increase in proliferative capacity (Figure 3.3C). This 
proliferation index, in essence, converted what was essentially a largely quiescent 
population of cells into cells that were rapidly dividing. These results indicated that p53 
loss and MRN deficiency were not epistatic to each other, and that MRN complex may 
have a separate critical function other that downstream p53 activation that may be 
contributing to this phenotype.  
3.3.4. MRE11 Mediates A P53-Independent G2/M DNA Damage Checkpoint  
To further understand what may be contributing to the difference in proliferation, 
we next decided to directly compare the MycOETrp53-/- vs. MycOETrp53-/-Mre11ATLD/ATLD 
pMMECs. Due to prior observations of Mre11 mediating the radiation-induced G2 
checkpoint, we evaluated the frequency of G2/M arrest in each cohort, and defined arrest 
as entry into G2 proceeded by a lack of mitotic cytokinesis or anaphase for at least ½ of 
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the imaging time ( 36 hours). These cells were more likely to be in permanent G2/M arrest 
rather than transient G2 delay. In this manner, we discovered that G2/M arrest frequency 
was 31% in cells with Mre11, whereas in pMMECs where Mre11 deficiency was 
established, the G2/M frequency was significantly lower at 4.8% (p<0.01, Fisher’s Exact 
Test, Figure 3.3D).  
To evaluate this further, we plotted the individual phase lengths of sgControl vs. 
sgMre11 pMMECs that were within the field of view for the entire duration of imaging 
(Figure 3.3E). Consistent with the observations of increased frequency of G2/M arrest, 
the length of G2 was significantly prolonged in the MycOETrp53-/-  pMMECs, and the mean 
G2 length was ~20 hours, whereas MycOETrp53-/-Mre11ATLD/ATLD cells entered G2 and 
completed mitosis within 10 hours, or roughly half the time (Figure 3.3E, p<0.01 by 
Student’s t-test).  
3.3.5. Mitotic Fates In MRE11 Deficiency 
Due to the complexity of the imaging dataset and the diversity in mitotic outcomes 
seen, we sought to characterize the mitotic patterns observed. We sorted the events into 
5 main categories: mitosis, aberrant mitosis, re-replication, G2 arrest, and mitotic 
catastrophe (Figure 3.4A). Of these, the last two categories are non-viable events that 
force cells to exit cell-cycle with no observable re-entry into cell cycle during imaging. The 
first three categories enable continuation of cell cycle with daughter cells that continue to 
exhibit cell cycle activity (Figure 3.4A). Aberrant mitosis was characterized by 
asymmetrical mitotic events with binucleated cells or multi-nucleated cells undergoing 
cytokinesis to give rise to viable daughters capable of entering S phase in the next cell-
cycle (Figure 3.4A). Re-replication was particularly striking, in normal somatic cells 
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replication is contained to one contiguous period of time in which PCNA foci appear. 
However, in cells with re-replication, there are two or more periods of PCNA foci formation 
that are interspersed between periods of resolution which indicate entry into G2 phase 
(Figure 3.4A).  
 In the 2000’s, the phenomenon of re-replication was thought to be primarily 
attributed to mis-licensing or mis-regulation of cellular replicasome complexes at origins, 
in large part due to aberrant Cyclin E activity179. However, in the past decade, extensive 
re-replication has been overserved in tumor cell lines with disruption of mammalian Cdt1 
via over-expression180. Cdt1 is loaded onto chromatin in the absence of Cyclin E and is 
progressively destroyed during S phase to prevent re-replication. Fascinatingly, while 
over-expression of Cdt1 causes significant re-replication in tumor lines, it does not have 
the same effect in primary cells. Cimprich, Cortez, Vaziri, and Liu have shown in a series 
of critical papers that this is inability of Cdt1 over-expression to cause re-replication in 
primary cells is due to the presence of p53-, ATM- and ATR-dependent checkpoint 
responses181–184. Primary cells will inhibit re-replication even in the context of mis-
regulation of licensing factors if the DNA damage response is activated and master 
kinases are engaged by long stretches of ssDNA that accumulate in under-replicated 
cells182. However, it is unknown whether these same mechanisms curtail re-replication 
during activation of oncogenes at early stages of neoplasia and additionally, it remains 
unclear if this checkpoint response is entirely p53-dependent or may have alternative 





Figure 3.4 Mitotic Characterization of Mre11 Deficient pMMECs. A, Representation 
of 5 different mitotic cell fates that were utilized to characterize cells. The top three 
outcomes are viable outcomes that enable cells to continue to cell-cycle. The final two 
outcomes are terminal events such as permanent G2 arrest or mitotic catastrophe which 
induces cell death and nuclear degradation. B, Percentage of cells in each mitotic 
outcome. Normal mitosis was defined as mononuclear cells giving rise to 2 daughter cells 
post cytokinesis. Aberrant mitosis was characterized by asynchronous cell division or 
cytokinetic failure. Re-replication was defined as cells that re-entered S phase (induction 
of 2nd round of PCNA foci) post G2. G2/M arrest was quantified as entry into G2 >36 
hours with no mitotic event. Mitotic catastrophe was characterized as mitosis with nuclear 
fragmentation and no subsequent cell-cycle activity ( S phase or Mitosis) in daughter cell 
fragments. sgControl treated cell percentages are the following: 13.3% (normal mitosis), 
4.4% (aberrant mitosis) 13.3%(Re-replication, 31.1% (G2 arrest), and 37.8% (mitotic 
catastrophe).  sgMre11 treated cell percentages are the following: 0% (normal mitosis), 





 Lastly, there are two non-viable cell cycle outcomes in our categorization scheme: 
extended G2 arrest and mitotic catastrophe (MC) (Figure 3.4A). G2 arrest has been 
previously described. MC has been defined in cell-cycle literature as an onco-
suppressive, evolutionary strategy for eliminating mitosis-incompetent cells185. The ability 
to trigger MC in epithelial cells has also been a therapeutic endpoint for many anti-cancer 
drugs as it is an effective way to eliminate unstable cancer cells54,132. Therefore, the ability 
to undergo MC is a critical fail-safe against cancer progression and is thought to be 
distinct from anti-proliferation cascades such as senescence and apoptosis. The current 
consensus is that there are three broad manners in which MC occurs: (1) cells die without 
exiting mitosis by arresting interminably in mitosis (i.e. in Anaphase or metaphase), (2) 
reach G1 and fail to undergo replication (no sign of S phase foci), and undergo cell death 
immediately in the new daughter cell, and (3) exit mitosis and undergo senescence185.  
Utilizing these frameworks, we were visually able to accurately categorize cells that 
underwent MC (Figure 3.4A).  
We quantitatively assessed what fraction of each of the MycOETrp53-/- vs. 
MycOETrp53-/-Mre11ATLD/ATLD pMMECs underwent each of the 5 outcomes. The most 
prominent observation was that cells with MRN deficiency evaded mitotic catastrophe 3x 
more often and 82% of the population of cells viably continued to cell-cycle by aberrant 
means (Figure 3.4B). In contrast to this, in MycOETrp53-/- cells, up to 70% of the population 
was eliminated via terminal cell-cycle events, in particular by mitotic catastrophe (Figure 
3.4B). Of note, in cells with MRN deficiency, normal mitotic events were completely 
absent for all of the cells that were evaluated, indicating a high level of cell cycle and 
checkpoint de-regulation.  
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In summation, these analyses reveal a role for Mre11 in protecting against mitotic 
entry or triggering mitotic failure if the G2-checkpoint fails. Mitotic catastrophes in 
sgControl cells are likely to be triggered by the presence of under-replicated DNA entering 
mitosis. However, the abundance of aberrant mitoses in sgMre11 cells also indicate 
increased DNA damage and aneuploidy entering mitosis, but this damage is ineffectively 
transduced into mitotic elimination of the abnormal cells (Figure 3.4B).  
3.3.6. MRE11 Deficiency Promotes Accelerated Mitotic Entry  
The results of our previous experiments revealed Mre11 as a mediator of G2-M 
checkpoint and as a critical player in elimination of cells via mitotic catastrophe in early 
pre-neoplastic lesions. We wanted to understand how this regulation of mitotic entry 
related to genome stability in late-stage neoplasia. Moreover, we further wanted to 
quantify the exact magnitude of effect Mre11 had on mitotic progression and damage 
sustained in newly created daughter cells. TNBC is characterized by rampant genome 
instability, and we hypothesized that long-standing MRN deficiency promotes accelerated 
mitotic entry which then may lead to ongoing genome instability in these tumors. To study 
this, we utilized Mre11 deficient tumor lines derived from Cas9-MycOE-p53-/- mice (Figure 
3.5A). The survival curves of this tumor induction study are still being collated and thus 
are not shown in this figure. We were able to utilize the first set of tumors formed to derive 
(2) Mre11 proficient and (3) Mre11 deficient tumor cell lines for the following studies 
(Figure 3.5B).  
 Using quantitative image-based cytometry (QIBC), we first quantified rate of mitotic 
entry via a S-M progression assay (Figure 3.5C). QIBC is a high-throughput platform for 
immunofluorescence (IF) based staining of cells to evaluate cell-cycle profiles en masse. 
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Cells are pulsed with EdU (to label S phase cells) for 30 minutes and then released into 
the mitotic synchronizing agent Nocodazole (NCD) or a DMSO control for up to 12 hours. 
At serial timepoints, cells are fixed and stained for nuclear content (DAPI), EdU (using 
Base-Click assay, see methods), and the mitotic marker H3-pS10 (phosphorylation of 
histone 3). Cells dually positive for the S phase and the mitotic markers at time of analysis 
are cells that have recently “progressed” from S phase to M phase (Figure 3.5C). We 
quantified the mitotic progression index at 0,3,6 and 12 h for Mre11 deficient vs. proficient 
cells in Figure 3.5D. Our results indicate that the rate of mitotic entry for Mre11 deficient 
cells is 5x greater than that of Mre11 deficient cells (Figure 3.5D, p<0.0001).These results 
highlight that this alone could account for the proliferation phenotype observed with Mre11 
deficiency in prior studies.  
 Next, to link mitotic entry to genome instability, we assessed inherited DNA 
damage in daughter cells in the Mre11 deficient cohort. Recently, under-replicated DNA 
(UR-DNA) that has entered mitosis has been shown to be packaged into 53BP1 nuclear 
bodies that emerge in early G1 of next cell-cycle114,186. These nuclear bodies contain the 
UR-DNA and enable replication attempts to fix the UR-DNA or to separate it from the 
nuclear genome during the next replication phase186. Thus, 53BP1 nuclear bodies are an 
established marker for UR-DNA that is a result of DNA damage entering mitosis in 
replication stress induced cells. We synchronized our Mre11 deficient vs. proficient tumor 
cells in mitosis and performed an NCD shake-off to harvest mitotic cells and re-plate them. 
We then allowed these newly re-plated cells to enter mitosis over the next 2 hours and 
harvested these cells for QIBC analysis of 53BP1 bodies (Figure 3.5F). To eliminate cells 
that have already entered the next S phase, we used an EdU pulse at time of harvest. 
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This ensured that the cells analyzed would only have 53BP1 nuclear bodies due to UR-
DNA and that we would not be detecting replication stress associated damage that was 
not inherited. To quantify these nuclear bodies, we plotted a frequency histogram of 
percent of cells with n number of 53BP1 bodies per nucleus (Figure 3.5G). Our results 
show that 10% of newly generated daughter cells without Mre11 have at least 1 nuclear 
body (Figure 3.5G). In comparison, ~1% of cells with Mre11 have any 53BP1 bodies 
(Figure 3.5G). Strikingly, only Mre11 deficient cells were found to harbor >1 53BP1 
nuclear body per nucleus, an indicator of high levels of UR-DNA (Figure 3.5G).  
 These results implicate Mre11 deficiency as a promoter of ongoing genome 
instability in tumors and link the checkpoint functions of Mre11 directly to its role in 
genome maintenance. Two recent publications have implicated that ATR-inhibitors 
accelerate mitotic entry112,187. It is likely that Mre11 is upstream of ATR kinase activation 
and may mediate this mitotic checkpoint through ATR and its downstream targets. As a 
result, future directions of this project should evaluate ATR-inhibitors and assess whether 





Figure 3.5 : Mre11 Deficiency Promotes Ongoing Genome Instability in Daughters. 
A, Stable cell line generation of murine mammary tumors. B, Western blot of 2 Mre11+/+ 
mammary tumors, and 3 Mre11 deficient mammary tumors. As a positive control, lysate 
from pMMECs was used. C, Quantitative Image Based Cytometry (QIBC) assay for 
assessment of S-M Progression of cells. Tumor cells were pulsed with 10uM EdU for 30 
minutes and washed with PBS. 100ng/ ml Nocodazole (NCD) was added to the treatment 
cohort. Cells were harvested immediately after wash-off, 3h, 6h, and 12 h post release 
into NCD or DMSO control and fixed with 2% Paraformaldehyde for staining. Cells were 
stained with DAPI (DNA content), Alexa-Fluor 637 (BaseClick assay for EdU detection of 
S phase cells) or H3-pS10 (mitotic marker). Cells dually positive for EdU and H3-pS10 
are cells that have recently entered mitosis after completing S phase. D, Quantification of 
the QIBC S-M progression assay, each datapoint is 5000 cells and an independent 
biological replicate. Relative increase in mitotic entry was normalized to %Edu and H3-
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ps10 dual positive cells in the Mre11+/+ cohort at 12 hours. p<0.0001=**** E, 53BP1 
Nuclear Body Assay for detection of transmission of under-replicated (UR-DNA) through 
mitosis into early G1 of daughter cells. Cells were treated with NCD for 16 hours and 
mitotic cells shaken-off and replaced for 2 hours to encourage entry into G1. Cells were 
pulsed with EdU to eliminate S phase cells in analysis, and stained for 53BP1. F, 
Quantification of E, each datapoint is 500 (Mre11+/+ cells) and 1500 (Mre11ATLD/ATLD 
cells). Frequency of cells with 0-6 53BP1 bodies per cell were evaluated and shown in 
logarithmic scale. 
 
3.3.7. Nuclear Aberrancies In MRE11 Deficient Cells 
The benefit live-cell imaging in experimental studies is the rich nature of the visual 
dataset itself. One striking observation that occurred during the blinded analysis of the 
imaging datasets was the prevalence of Polyploid Giant Cancer Cells (PGCCs) in all 
imaging beacons monitoring Mre11 deficient pMMECs (Figure 3.6A vs. B). PGCCs have 
been observed in clinically aggressive, metastatic breast cancers on tissue pathology and 
are indicators of high levels of chromosomal instability188. In contrast to these PGCCs, 
the sgControl treated pMMECs were characterized by large factions of quiescent 
fragmented nuclei (no S phase foci observed) (Figure 3.6A). The polyploid nature of the 
cells with MRN deficiency was also specific to pMMECs with p53 deficiency, i.e. this was 
not observed in the pMMECs with MycOE alone. The PGCCs in our study were 
characterized by their ability to continue proliferating through cell cycle even with highly 
aberrant nuclear structures (in the Mre11 deficient cohort, Figure 3.6B). States of 
aneuploidy have previously been described in cells with p53 loss; however, it is unclear 






Figure 3.6 : Mre11 Deficiency Impairs Micronucleus Formation. A, sgControl MMECs 
from live-cell imaging, 4 examples of cells with micronuclei (arrows). B, sgMre11 MMECs 
from live-cell imaging, the foci indicate these are S phase cells, 4 examples shown. C,  
Diagramatic depiction of micronucleus mediated interferon signaling. The question marks 
indicate scientific unknowns regarding MN formation and IRF3 activated Type 1 interferon 
transcription in Mre11 proficient vs. deficient cells. D, Experimental set-up for the 
micronucleus formation assay. Mouse embroynic fibroblasts (MEFs) were irradiated at 
10Gy and harvested immediately after, and up to 12 hours post irradiation, and stained 
with DAPI and imaged. Panels show examples of distinct micronucleus (left) and nuclear 
blebbing (right). E, Mre11 +/+ vs. ATLD/ATLD MEFs were evaluated for MN formation. 
Each datapoint is the average % micronucleated cells in an imaging beacon (n=25-50 
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cells/ beacon). Images from 3 different biological replicates per genotype were pooled for 
blinded analysis. p<0.05 = *, p<0.01 = **. F, Mre11 +/+ vs. ATLD/ATLD MEFs were 
evaluated for nuclear blebbing and nuclear membrane protrusions. Each datapoint is the 
average % cells with nuclear blebbing in an imaging beacon (n=25-50 cells/ beacon). 
Images from 3 different biological replicates per genotype were pooled for blinded 
analysis. p<0.01 = **, p<0.001=***. 
 
 To evaluate this, we studied the quiescent sgControl cells that are undergone MC 
and noted that these cells contained prominent, discrete cytoplasmic fragments of nuclear 
material. Micronuclei (MN) are nuclear segments that are present in the cytoplasm of 
cells, and often contain DSBs or other genomic fragments (white arrows, Figure 3.6A)189. 
How they are formed has become a topic of active investigation in the past five years. To 
begin, micronuclei have a close association with genome instability and chromosomal re-
arrangements; particularly chromothripsis190. Chromothripsis is a type of genomic 
instability where cells undergo rapid genome re-rearrangements and chromosomal 
breakages within a matter of several cellular divisions, creating a punctuated model for 
cancer evolution. This type of genome chaos is advantageous as it offers cells the ability 
to accumulate a  large mutational burden in a short amount of time.  There are two main 
theories about the link between micronuclei and genome instability. One, during 
chromothripsis, large deletions or chromosomal fragments may be incurred by the cell 
which are then packaged as micronuclei. Two, genome fragments that are already 
present in micronuclei may undergo partial replication which are then re-integrated into 
the nuclear genome resulting in copy number abnormalities190. Both theories are not 
mutually exclusive and there is overall consensus that cells with high levels of genome 
instability are likely to have micronuclei and that MN formation can also be exogenously 
induced by irradiation.  
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In the pMMECs with Mre11 deficiency, the prevalence of micro-nucleated cells 
was rare, even though many of the cells were multi-nucleated (Figure 3.6B). We 
hypothesized that Mre11 complex formation may be required for micronuclei formation. 
To assess this, we used mouse-embryonic fibroblasts (MEFs) with Mre11-ATLD1 
mutations to assess micronuclei formation and signaling (Figure 3.6C). These 
Mre11ATLD/ATLD MEFs were exposed to irradiation (a well-known inducer of MN)  and their 
ability to form micronuclei was compared to WT (Mre11+/+) MEFs (Figure 3.6D). In our 
studies, Mre11ATLD/ATLD MEFs were unable to form micronuclei for up to 12 hours post 
radiation (Figure 3.6E). Furthermore, while micronuclei formation was reduced in the 
Mre11ATLD/ATLD MEFs, nuclear blebbing (where the nucleus protrudes due to loss of 
contiguous nuclear membrane against the nucleoplasm) was highly prevalent (Figure 
3.6F). Nuclear membrane blebbing has also been described as a precursor step to 
micronuclei formation; however, here the Mre11ATLD/ATLD cells are unable to form 
micronuclei after this step. This supports the hypothesis that complex function is required 
for micronuclei formation.  
3.3.8. MRE11 Mediates Micronucleus Formation in Response To Radiation 
The presence of MN is often associated with senescence and elimination of 
chromosomally unstable cells by the innate immune system as MN often activate 
cytoplasmic  damage sensors189. Cytosolic  DNA has been a marker for cellular infection 
by viral pathogens. Thus, a host of inflammatory cytokines are activated by the presence 
of cytoplasmic dsDNA. Cytosolic sensors of DNA damage have recently come to attention 
due to their ability to enhance the effects of radiation in what is known as the “abscopal 
effect.” Simply defined, the abscopal effect is the observation that a tumor focus outside 
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of the field of irradiation is impacted by radiotherapy.  Irradiation induces MN formation 
and thereby activates inflammatory cascades that produce chemokines which in turn 
trigger phagocytic innate immune cells101 (Figure 3.6A). In this manner, the immune 
system is a key player in the abscopal effect. We performed several experiments to 
assess whether Mre11ATLD/ATLD MEF cells could trigger an interferon response to 
radiation. We hypothesized that Mre11ATLD/ATLD MEFs would mount a less robust 
interferon response to irradiation compared to WT MEFs. 
3.3.9. MRE11 And Interferon Signaling  
To assess whether Mre11ATLD/ATLD MEFs were able to induce an interferon (IFN) 
response, we performed RT-qPCR experiments evaluating transcription of IFNB1 and 
Interferon Stimulating Gene (ISG) post irradiation (Figure 3.7A). Our experiments indicate 
the Mre11ATLD/ATLD MEF cells are unable to mount a robust interferon response to 
irradiation in contrast to WT MEFs (Figure 3.7B). Subsequently we attempted to abrogate 
the WT MEF response with both a commercially available Mre11 inhibitor (Mirin) and an 
inhibitor to the downstream kinase ATM (ATMi) (Figure 3.7C,D). Treatment with Mirin did 
not reduce the interferon response in WT MEFs, suggesting that the Mre11 exonuclease 
inhibited by Mirin is not responsible for interferon responses (Figure 3.7C). Treatment 
with ATMi increased the interferon response noted in WT MEFs, suggesting that ATMi 
therapy may increase cytosolic dsDNA concentrations or further enable interferon 
signaling (Figure 3.7D). Further reconstitution experiments with various mutations of 
Mre11 will help delineate the exact function of Mre11 that is required for both 




Figure 3.7 : Mre11 Deficient Cells have Impaired Interferon Signaling. A, Schematic 
describing the irradiation IR) induced micronucleus formation assay. 1x10^6 cells are 
plated in a 10cm dish 24 h prior to irradiation and media changed prior to IR. Cells are 
irradiated at 3 or 5 Gy and placed in 37C incubator for 72 hours for MN formation through 
mitosis. Cells are trypsnized and RNA extracted for cDNA synthesis and RT-qPCR. B, 
Irradiation induced Interferon B1 (IFNB1) and Interferon Stimulating Gene 56 (ISG56) 
transcriptional up-regulation in WT (Mre11+/+) MEFs compared to ATLD/ATLD MEFs. 
p<0.01 = **, results are average n=3 biological replicates. C, Cells were pre-treated with 
50 uM Mirin (Mre11 inhibitor) 2 hours prior to irradiation. p<0.001 = ***., results are 
average n=3 biological replicates. C, Cells were pre-treated with 10 uM ATMi (KU55933) 
2 hours prior to irradiation. p<0.0001 = ****, and p<0.001 = *** results are average n=3 
biological replicates. Statistical analyses performed with Student’s t-test 
 
As we encountered these results, we additionally challenged the Mre11ATLD/ATLD 
deficient cells with a variety of classical interferon inducing agents to see if we could alter 
the IFN response in these cells compared to WT MEFs (Figure 3.8A). Due to several 
patient case reports of MRE11 mutations resulting in auto-inflammatory syndromes and 
new publications on cytosolic binding partners of Mre11, we hypothesized that Mre11 
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may have a cytosolic role in binding to dsDNA and initiating immune responses. We 
transfected dsDNA and ssDNA (as control) from Herpes Simplex Virus (HSV), Vaccinia 
Virus (VACV), and Interferon Stimulating DNA (ISD) into Mre11ATLD/ATLD vs. WT MEFs 
and measured interferon transcriptional responses (Figure 3.8B-D). These agents are 
often used by immunologists to trigger interferon responses in cells191. Intriguingly, the 
Mre11ATLD/ATLD MEFs significantly underperformed in their ability to induce transcription 
of IFNB1 by all three agents (VACV, ISD, and HSV) compared to the WT MEFs (Figure 
3.8B-D, left panels). VACV also induced a significantly different ISG56 response in 
Mre11ATLD/ATLD vs. WT MEFs, while ISD and HSV induced differential responses with 
respect to ISG56 (Figure 3.8B-D, right panels). In summary, these results indicate that 
Mre11ATLD/ATLD cells have a functional deficiency in triggering interferon B1 signaling in 





Figure 3.8 : Mre11 Deficient Cells have Functional Defects in Response to Classical 
Interferon Stimulating Agents. A, Schematic for RT-qPCR experimental set-up. 
Interferon stimulating dsDNA was transfected into 1x 10^6 mouse embryonic fibroblasts 
(MEFs) utilizing Lipofectamine 3000. 24 hours post transfection, cells were harvested and 
RNA extracted using Qiagen RNeasy Kit. RT-qPCR for two interferon stimulating genes 
were performed: interferon B1 (IFNB1) and interferon Stimulating Gene 56 (ISG56). B, 
RT-qPCR data for interferon response to transfected Herpes Simplex Virus (HSV) 
dsDNA, with ssDNA as negative control. dsDNA was created annealing ssDNA 
oligos.(p=0.002, IFNB1 and p=0.1, ISG56) C, RT-qPCR data for interferon response to 
transfected Vaccinia Virus (VACV) dsDNA, with ssDNA as negative control. (p=0.003, 
IFNB1 and p=0.0556 ISG56) D, RT-qPCR data for interferon response to transfected 
Interferon Stimulating DNA which is exists as duplex DNA. For this experiment, RNA from 
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untransfected (UT) cells was used as a negative control. (p=0.011, IFNB1 and p=0.066 
ISG56). For all RT-qPCR experiments, the left panel (IFNB1) and the right panel (ISG56). 
Data from n=3 replicates are shown with +/- error. 
 
In conclusion, our utilized a systematic in vivo DDR CRISPR library screen which 
revealed Mre11 to be a critical DDR gene in tumor suppression during early neoplasia. 
We then validated the results of the screen and investigated prior phenotypes associated 
with Mre11 deficiency to assess the role of Mre11 in regulating cell-cycle in pre-neoplasia. 
Our results highlight a key role for Mre11 in regulating G2-M checkpoint in response to 
oncogenic induction. This G2 checkpoint function is independent of p53-activation and is 
critical for restraining mitotic entry. Moreover, the same mechanism contributes to the 
loss of genome stability seen in Mre11 deficiency and as mitotic entry of UR-DNA is 
inherited by daughter cells in early G1 53BP1 nuclear bodies. Thus, Mre11 not only 
curtails initial tumor proliferation but also prevents ongoing genome instability in murine 
models of TNBC. Following close assessment of nuclear abnormalities seen in live-cell 
imaging, we reveal a novel interaction with Mre11 deficiency and micronucleus formation. 
Mre11 deficient cells have impaired formation of MN in response to radiation and 
importantly, lack functional interferon signaling that is critical for in vivo recruitment of 
innate immune cells and also for the abscopal response to radiotherapy. These results 
pave the way for future studies that investigate the clinical relevance of using DNA 
damage checkpoint inhibitors like ATRi and immune profiling in Mre11 deficiency with 




3.4. Materials and Methods 
3.4.1. Cell Lines 
WT  and ATLD/ATLD Mouse Embryonic Fibroblasts (MEFs) were SV-40 large T 
antigen immortalized12,20,22. 293T cells were purchased from ATCC (CRL11268). 
These cell lines were maintained in Dulbecco’s modified Eagle’s medium (DMEM), with 
10% Bovine Calf Serum (Hyclone BCS) and 2 mM L-glutamine (ThermoFisher). LA-7 
cells were obtained from ATCC (CRL2283) and were maintained in DMEM/F12 medium 
supplemented with 10% fetabl bovine serum, 20mM HEPES, and 10ug/ml Insulin. LA-7 
cells are irradiated at 70 Gy ionizing radiation using a Rad Source R2000 irradiator prior 
to use as feeder cells in experiments with primary mammary epithelial cells. All cells were 
maintained at 37 °C in an atmosphere of 5% CO2. Cells in culture were routinely 
monitored for mycoplasma contamination using the Plasmo Test™ (Invivogen). 
3.4.2. Primary Murine Mammary Epithelial Cells 
pMMECs were grown as previously described in PMID: ***. were derived by 
harvesting the 4th and 5th mammary glands from 6-week-old female transgenic mice with 
the desired genotype. Glands were manually disrupted using surgical scissors and were 
incubated in Liberase digestion medium (EpiCult-B Mouse Medium Kit (Stem Cell 
Technologies, 285 Units Collagenase Type 3 (Worthington), 20mM HEPES (GIBCO), 20 
ug/mL Liberase Blendzyme 2 (Roche) and shaken (vertically) at 37 oC overnight. The 
overnight digests were then spun down and resuspended in 3 mls trypsin with EDTA and 
1000U DNase and incubated at 37 oC for 5 min. DMEM with 10% serum was used  to 
quench the enzymatic digest. Cells were spun down and resuspended in 10U Dispase 
(Stem Cell Technologies) and 1000U DNase I (Worthington Biochemical) and incubated 
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at 37 oC for 5 min. Cells were washed twice with LA-7 medium and the resulting cells 
were resuspended in EpiCult-B Mouse Medium Kit (Stem Cell Technologies) and seeded 
onto Cultrex 3D-Culture Matrix (Trevigen) coated 6 well plates. To coat the 6-well plates, 
the 3D-culture collagen was mixed with 10mM Acetic Acid (at ratio specified by 
manufacture) and incubated for 40 minutes and washed 3x with PBS. For longer term cell 
growth experiments, pMMECs were seeded on lethally irradiated LA-7 cells and cultured 
in LA-7 medium. For cells that require viral transduction for experimentation purposes, 
pMMECs are infected for 48 hours in isolation after which cells are washed and grown for 
an additional 24 hours prior to trypsinization and addition to LA7 cells for long-term 
culture. All cells were cultured to 80% confluence then passaged by trypsinization. Cells 
were tested monthly for mycoplasma using PlasmoTest Kit. 
3.4.3. DDR CRISPR Library  
The sgGuide pooled library was previously published with sgGuide sequences on 
PMID: . The CRISPR library sgRNAs were PCR amplified using AmpliTaq Gold® 360 
DNA Polymerase (ThermoFisher) with forward primer ArrayF and reverse primer ArrayR 
followed by PCR purification (Qiagen) to then use for Gibson Cloning. The CRISPR library 
cassette was cloned into lentiCRISPRV2-Lumifluor (derived from lenti-CrisprV2a gift from 
Feng Zhang, Addgene plasmid # 52961, see cloning). Post- the Gibson reaction, we 
transformed the plasmid into Endura Competent cells via electroporation and plated into 
twelve, 10 cm petri dishes (VWR) containing LB agar (ThermoFisher) with 100 µg/ml 
carbenicillin (ThermoFisher). Colonies were selected and combined for DNA extraction 
(Qiagen). The presence of the sgRNA was verified by Sanger sequencing using the 
ArrayF primers.  
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3.4.4. Viral Production And Infection  
HEK 293T cells were transfected with viral packaging plasmids: psPax2 (Addgene 
#12260) and pMD2.G (Addgene #12259) using Linear Polyethlenimamine (PEI) and the 
desired plasmid containing sgRNA. 16 hours post transfection, cells were washed, and 
supernatant collected at 48h and 72h. Pooled supernatant was spun to eliminate cellular 
debris at 1000xg for 5 minutes and subsequently filtered at 0.45 um. To concentrate 
lentivirus, filtered supernatant was spun at 21,000 rpm for 2 hours at 16 oC. Post spin-
down, the remaining media was removed and the viral pellet resuspended in 1:100 th of 
initial volume in PBS overnight at 4 oC. Virus was then aliquoted into Eppendorf tubes in 
and stored in -80 oC until use. Viral aliquots were then thawed right before use to avoid 
freeze-thaw cycles.  
3.4.5. Transgenic Mouse Models   
Mice used in this study were previously described in PMID# were housed in the 
Division of Comparative Medicine at the University of North Carolina at Chapel Hill. 
R26LSL-Cas9 (JAX#024857) and R26LSL-MycOE (JAX#020458) transgenic mouse 
strains were obtained from the Jackson Laboratory. Trp53fl/fl mouse strains were gifts 
from the Perou laboratory, and originally obtained from the Frederick National Laboratory 
for Cancer Research (Strains #01XC1 and #01XC2). To create the desired genotype, 
R26LSL-Cas9  mice were crossed to R26LSL-MycOE  to first create Cas9-MycOE mice 
which were then finally crossed to Trp53fl/fl to create R26Cas9/Cas9-MycOE-Trp53fl/fl 
female mice.  
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3.4.6. DDR In-vivo CRISPR Screen Tumor Generation  
For the DDR In-vivo CRISPR screen, six to twelve-week-old female 
R26Cas9/Cas9-MycOE-Trp53fl/fl mice received bilateral intraductal injections, into the 
fourth mammary gland of LentiCRISPR-Cre-V2-DDR-Lumiflour lentivirus. Each gland 
received 10ul of virus into the ductal tree, fore ease of injection, virus was dyed with 
Evan’s Blue powder. The intraductal injections were performed by Dr. Brian Cooley of the 
UNC Animal Surgery Core.  
3.4.7. MYC-P53 Tumor Survival Studies  
For tumor induction studies for the Mre11 deficiency vs. proficiency survival study, 
six to twelve-week-old female R26Cas9/Cas9-MycOE-Trp53fl/fl mice received bilateral 
intraductal injections, into the fourth mammary gland, containing 5x10^5 transduction 
units (TU) of either LentiCRISPR-Cre-V2-sgControl-Lumifluor (Cre-sgControl) or 
LentiCRISPR-Cre-V2-sgMre11-Lumifluor (Cre-sgMre11).   
3.4.8. Tumor Harvest and Stable Cell Line Generation for all Tumor Studies  
Tumor harvest guidelines used in this protocol were originally obtained from 
PMID# with. Mouse cohorts were bilaterally palpated for the development of mammary 
tumors twice weekly, and three times weekly after mammary tumors had formed to 
monitor tumor size. Mice were euthanized when tumors reached > 15 mm in size on either 
gland and in accordance with UNC Institutional Animal Care and Use Committee (IACUC) 
guidelines. At necropsy, each mammary tumor was sectioned into four pieces. Two 
pieces were banked as fresh frozen tissue for future studies and RNA/DNA extraction. 
One section (the part attached to gland 5) was fixed in 4% paraformaldehyde and 
processed for paraffin embedding and H&E staining (Histoserv Inc.). This ensured that a 
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non-injected control (Gland 5) would be present for histology analysis in the same sample. 
The final piece was taken for tumor line creation. The tumor pieces were mechanically 
disrupted using surgical blades on sterilized glass petri dishes to remove lipidaceous 
tissue. Tumor pieces were incubated in digestion medium (DMEM, 10% FBS, 1mg/ml 
Collagenase Type 3, 1mg/ml Hyaluronidase) and shaken (horizontally) at 37 oC for four 
hours. The resulting digestion was spun down and resuspended in trypsin with DNase 
and incubated at 37 oC for 5min. DMEM with 10% FBS was added to neutralize the 
trypsin. Cells were spun down and resuspended in Dispase and deoxyribonuclease and 
incubated at 37 for 5min. Cells were washed twice with 10% FBS in DMEM and passed 
through a 70 mm filter. The resulting cells were resuspended in LA-7 media and 
immediately seeded into co-culture with irradiated LA-7 feeder cells. The cells were 
cultured over 10 passages and analyzed via flow for GFP expression to monitor tumor 
cell outgrowth. Tumor lines were then utilized for downstream assays when GFP 
expression reached >90%. 
3.4.9. Cloning 
3.4.9.1. Lenticrispr-Cre-V2-Sgrna Plasmid  
 LentiCRISPR-Cre-V2 plasmid was previously described in (Cell Reports Paper 
PMID#). Using BSMB1 restriction sites, short-guide RNA sequences for a 53BP1 intron 




3.4.9.2. Lenticrispr-Cre-V2-Sgrna-H2b-Gfp Plasmid   
LentiCRISPR-Cre-V2-Lumifluor plasmid was previously described in (Cell Reports 
Paper PMID#). To insert H2B-GFP into the region we created a geneBlock (IDT) H2B 
fused to GFP using a sequence from a published H2B-GFP plasmid on Addgene 
(#11680). Using PCR based amplification of the LentiCRISPR-Cre-V2-Lumifluor plasmid, 
we used Gibson cloning (HiFi DNA Assembly Master Mix; NEB) to replace Lumifluor with 
H2B-GFP.  
3.4.9.3. Immunofluorescence  
Cells were fixed with 3% Paraformaldehyde for 15 min at RT, followed by 
permeabilization with 0.25% TritonX-100 in PBS. Cells were subsequently processed for 
immunostaining experiments using the antibodies listed below. For experiments in which 
S phase cells were imaged, cells were treated with 10uM EdU pulse for 30 minutes and 
washed 1x with PBS. Nuclei were visualized by staining with DAPI. The primary antibody 
used was 53BP1 (1:500 for immunofluorescence, Bethyl, A300-272A). The secondary 
antibodies were: FITC Goat Anti Rabbit IgG (H + L) (1:500, Jackson ImmunoResearch, 
111-095-144).EdU was detected using the EdU-Click 647 Protocol (BaseClick). Images 




CHAPTER 4 – CONCLUSIONS 
The research reported here identifies a novel role for the MRN complex in 
activating a p53-independent, G2/M checkpoint in response to oncogenic replication 
stress in pre-neoplastic lesions.  We highlight the distinct mitotic phenotypes that cells 
with or without MRN deficiency incur. The presence of MRN is correlated with increased 
arrest frequency and catastrophic mitoses, suggesting that MRN is actively involved in 
eliminating cells with DNA damage via cell-cycle regulation. We demonstrate that  MRN 
deficiency increases mitotic entry and results in propagation of replication stress into 
53BP1 nuclear bodies in the early G1 phase of daughter cells. These results resolve the 
mechanism by which MRN deficiency gives rise to both a proliferative advantage and 
ongoing genomic instability. 
 In Chapter 3, we shed insights into how MRN complex may also have a role in 
tumor immunity. Our data indicate that MRN complex deficient cells have a functional 
defect in micronucleus formation which may have in vivo consequences for innate 
immune signaling and abscopal responses to radiotherapy. Interestingly, our data 
demonstrate that these cells may also have a defect in interferon responses. While this 
data is intriguing, the relationship between the DDR and the immune system is complex 
and more research is necessary to gain a better understanding of how the MRN complex 
functions to gives rise to micronuclei and helps to signal the presence of cytoplasmic 
DSBs. To do this, re-constitution experiments in MRN deficient lines with various
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 functional mutants (e.g. nuclease dead) of Mre11 are required to understand which 
functions of Mre11 are essential for micronucleus formation. Furthermore, immune 
profiling of MRN deficient tumors is also necessary to clarify whether the lack of interferon 
response is translates into reduced immune infiltration in vivo.  
 This dissertation also explored altered DNA damage responses in p53-deficiency. 
Currently, there is no consensus to explain why p53 deficiency in cells leads to resistance 
to DNA damaging therapy; even though the observation of therapeutic resistance has 
been documented for many decades. In Chapter 2, we demonstrate that p53 deficient 
cells have hyperactive end-joining repair capacities that render them less vulnerable to 
radio-mimetic drugs and by extension, other double strand break inducing agents. Using 
live-cell imaging we examine the accelerated repair of DNA damage foci in p53-deficient 
cells. Partial sensitivity to DSB-inducing agents can be restored with DNA-PKi treatment, 
which inhibits the key master regulatory kinase in the NHEJ pathway. Treatment with 
DNA-PKi promotes mitotic catastrophe in p53-deficient cells. However, some cells still 
escape cell-death. In these cells, we determined that up-regulated Polymerase Theta 
expression and alternative end-joining repair mediate resistance to DNA-PKi. Finally, 
combinatorial suppression of DNA-PK and Pol-Theta restores radiosensitivity of p53-
deficient cells to the same level as p53 wildtype cells.  
 Clinically, our results indicate that the therapeutic benefit of radiotherapy in p53-
deficient cancers can be potentiated with the use of DNA-PKi. Recent clinical reports have 
shown that p53 pathway alterations predict radioresistance in aggressive pediatric  
Diffuse Intrinsic Pontine Gliomas. Preliminary assessment of Rhabdomyosarcoma and 
Ewing Sarcoma (ES) patients in the MSK-IMPACT dataset identified an increased risk for 
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inferior irradiated tumor control in pediatric patients with p53-pathway mutations. To 
explore the therapeutic ramifications of our studies, future experiments should compare 
the efficacy of pre-treatment with DNA-PKi before radiotherapy to radiotherapy treatment 
alone in sarcoma cell lines and eventually, in in vivo mouse models of ES. Our results 
suggest that dual treatment may potentiate radiosensitivity only in p53-deficient cancer 
cell lines. DSB inducing chemotherapies present another therapeutic context in which 
end-joining repair is crucial, and should also be evaluated in combination with DNA-PKi 
treatment. Moreover, the current development of the first inhibitors to Polymerase-theta 
creates an exciting landscape to evaluate the use of DNA-PKi in combination with these 
newly synthesized compounds. Finally, as many DNA-PKi compounds are currently being 
evaluated in clinical trials as radiosensitizing agents, these results pave the way for 
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